# EDGAR Filing Document

**Accession Number:** 0001825224
**File Stem:** 0001670254-25-000662
**Filing Date:** 2025-6
**Character Count:** 205380
**Document Hash:** 71292d79856ff4b18016d70eda36a257
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001670254-25-000662.hdr.sgml**: 20250620

**ACCESSION NUMBER**: 0001670254-25-000662

**CONFORMED SUBMISSION TYPE**: C/A

**PUBLIC DOCUMENT COUNT**: 12

**FILED AS OF DATE**: 20250620

**DATE AS OF CHANGE**: 20250620

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OsNovum, Inc.
- **CENTRAL INDEX KEY:** 0001825224

**ORGANIZATION NAME:**
- **EIN:** 851571726
- **STATE OF INCORPORATION:** WY

**FILING VALUES:**
- **FORM TYPE:** C/A
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 020-34287
- **FILM NUMBER:** 251060233

**BUSINESS ADDRESS:**
- **STREET 1:** 1051 OLSEN ST, 3611
- **CITY:** HENDERSON
- **STATE:** NV
- **ZIP:** 89011
- **BUSINESS PHONE:** 5106982462

**MAIL ADDRESS:**
- **STREET 1:** 1051 OLSEN ST, 3611
- **CITY:** HENDERSON
- **STATE:** NV
- **ZIP:** 89011

## Ex-99

### Attached PDF Documents

**Attachment 1:** `document_1.pdf`

# Form C

## Cover Page

Name of issuer:
OsNovum

Legal status of issuer:
Form: Corporation
Jurisdiction of Incorporation/Organization: WY
Date of organization: 6/9/2020

Physical address of issuer:
1051 Olsen St, 3611
Henderson NV 89011

Website of issuer:
http://www.OsNovum.com

Name of intermediary through which the offering will be conducted:
Wefunder Portal LLC

CIK number of intermediary:
0001670254

SEC file number of intermediary:
007-00033

CRD number, if applicable, of intermediary:
283503

Amount of compensation to be paid to the intermediary, whether as a dollar amount or a percentage of the offering amount, or a good faith estimate if the exact amount is not available at the time of the filing, for conducting the offering, including the amount of referral

and any other fees associated with the offering:

7.5% of the offering amount upon a successful fundraise, and be entitled to reimbursement for out-of-pocket third party expenses it pays or incurs on behalf of the Issuer in connection with the offering.

Any other direct or indirect interest in the issuer held by the intermediary, or any arrangement for the intermediary to acquire such an interest:

No

Type of security offered:

☐ Common Stock
☑ Preferred Stock
☐ Debt
☐ Other

If Other, describe the security offered:

Target number of securities to be offered:

1,250

Price:

$40,000,000

Method for determining price:

Dividing pre-money valuation $19,532,200.00 by number of shares outstanding on fully diluted basis.

Target offering amount:

$50,000.00

Oversubscriptions accepted:

☑ Yes
☐ No

If yes, disclose how oversubscriptions will be allocated:

☐ Pro-rata basis
☐ First-come, first-served basis
☑ Other

If other, describe how oversubscriptions will be allocated:

As determined by the issuer

Maximum offering amount (if different from target offering amount):

$200,000.00

Deadline to reach the target offering amount:

4/30/2026

NOTE: If the sum of the investment commitments does not equal or exceed the target offering amount at the offering deadline, no securities will be sold in the offering, investment commitments will be cancelled and committed funds will be returned.

Current number of employees:

4

|  | Most recent fiscal year-end: | Prior fiscal year-end: |
| --- | --- | --- |
| Total Assets: | $9,440.00 | $137.00 |
| Cash & Cash Equivalents: | $9,440.00 | $137.00 |
| Accounts Receivable: | $0.00 | $0.00 |
| Current Liabilities: | $0.00 | $0.00 |
| Non-Current Liabilities: | $0.00 | $4,643.00 |
| Revenues/Sales: | $0.00 | $0.00 |
| Cost of Goods Sold: | $0.00 | $0.00 |
| Taxes Paid: | $0.00 | $0.00 |
| Net Income: | ($55,814.00) | ($22,650.00) |

Select the jurisdictions in which the issuer intends to offer the securities:

AL, AK, AZ, AR, CA, CO, CT, DE, DC, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, VA, WA, WV, WI, WY, BS, GU, PR, VI, 1V

## Offering Statement

Respond to each question in each paragraph of this part. Set forth each question and any notes, but not any instructions thereto, in their entirety. If disclosure in response to any question is responsive to one or more other questions, it is not necessary to repeat the disclosure. If a question or series of questions is inapplicable or the response is available elsewhere in the Form, either state that it is inapplicable, include a cross-reference to the responsive disclosure, or omit the question or series of questions.

Be very careful and precise in answering all questions. Give full and complete answers so that they are not misleading under the circumstances involved. Do not discuss any future performance or other anticipated event unless you have a reasonable basis to believe that it will actually occur within the foreseeable future. If any answer requiring significant information is materially inaccurate, incomplete or misleading, the Company, its management and principal shareholders may be liable to investors based on that information.

## THE COMPANY

1. Name of issuer:
OsNovum

## COMPANY ELIGIBILITY

2. ☐ Check this box to certify that all of the following statements are true for the issuer.

- Organized under, and subject to, the laws of a State or territory of the United States or the District of Columbia.
- Not subject to the requirement to file reports pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934.
- Not an investment company registered or required to be registered under the Investment Company Act of 1940.
- Not ineligible to rely on this exemption under Section 4(a)(6) of the Securities Act as a result of a disqualification specified in Rule 503(a) of Regulation Crowdfunding.
- Has filed with the Commission and provided to investors, to the extent required, the ongoing annual reports required by Regulation Crowdfunding during the two years immediately preceding the filing of this offering statement (or for such shorter period that the issuer was required to file such reports).
- Not a development stage company that (a) has no specific business plan or (b) has indicated that its business plan is to engage in a merger or acquisition with an unidentified company or companies.

INSTRUCTION TO QUESTION 2: If any of these statements are not true, then you are NOT eligible to rely on this exemption under Section 4(a)(6) of the Securities Act.

3 Has the issuer or any of its predecessors previously failed to

comply with the ongoing reporting requirements of Rule 202 of Regulation Crowdfunding?

☐ Yes ☑ No

## DIRECTORS OF THE COMPANY

4. Provide the following information about each director (and any persons occupying a similar status or performing a similar function) of the issuer.

| Director | Principal Occupation | Main Employer | Year Joined as Director |
| --- | --- | --- | --- |
| Gregory Gene Steiner | Biotech officer | OsNovum | 2020 |
| Roslynn Lilian Steiner | Biotech officer | OsNovum | 2020 |

For three years of business experience, refer to Appendix D: Director &amp; Officer Work History.

## OFFICERS OF THE COMPANY

5. Provide the following information about each officer (and any persons occupying a similar status or performing a similar function) of the issuer.

| Officer | Positions Held | Year Joined |
| --- | --- | --- |
| Gregory Gene Steiner | CEO | 2020 |
| Daniel Vargas | VP Marketing | 2020 |
| Roslynn Lilian Steiner | President | 2020 |

For three years of business experience, refer to Appendix D: Director &amp; Officer Work History.

**INSTRUCTION TO QUESTION 5:** For purposes of this Question 5, the term officer means a president, vice president, secretary, treasurer or principal financial officer, comptroller or principal accounting officer, and any person that routinely performing similar functions.

## PRINCIPAL SECURITY HOLDERS

6. Provide the name and ownership level of each person, as of the most recent practicable date, who is the beneficial owner of 20 percent or more of the issuer's outstanding voting equity securities, calculated on the basis of voting power.

| Name of Holder | No. and Class of Securities Now Held | % of Voting Power Prior to Offering |
| --- | --- | --- |
| Roslynn Lilian Steiner | 235200.0 Common | 49.0 |
| Gregory Gene Steiner | 244800.0 Common | 51.0 |

INSTRUCTION TO QUESTION 6: The above information must be provided as of a date that is no more than 120 days prior to the date of filing of this offering statement.

To calculate total voting power, include all securities for which the person directly or indirectly has or shares the voting power, which includes the power to vote or to direct the voting of such securities. If the person has the right to acquire voting power of such securities within 60 days, including through the exercise of any option, warrant or right, the conversion of a security, or other arrangement, or if securities are held by a member of the family, through corporations or partnerships, or otherwise in a manner that would allow a person to direct or control the voting of the securities (or share in such direction or control - as, for example, a co-trustee) they should be included as being "beneficially owned." You should include an explanation of these circumstances in a footnote to the "Number of and Class of Securities Now Held." To calculate outstanding voting equity securities, assume all outstanding options are exercised and all outstanding convertible securities converted.

## BUSINESS AND ANTICIPATED BUSINESS PLAN

7. Describe in detail the business of the issuer and the anticipated business plan of the issuer.

For a description of our business and our business plan, please refer to the attached Appendix A, Business Description &amp; Plan

INSTRUCTION TO QUESTION 7: Wefunder will provide your company's Wefunder profile as an appendix (Appendix A) to the Form C in PDF format. The submission will include all Q&amp;A items and "read more" links in an un-collapsed format. All videos will be transcribed.

This means that any information provided in your Wefunder profile will be provided to the SEC in response to this question. As a result, your company will be potentially liable for misstatements and omissions in your profile under the Securities Act of 1933, which requires you to provide material information related to your business and anticipated business plan. Please review your Wefunder profile carefully to ensure it provides all material information, is not false or misleading, and does not omit any information that would cause the information included to be false or misleading.

## RISK FACTORS

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment.

In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any

federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document.

The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature.

These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.

8. Discuss the material factors that make an investment in the issuer speculative or risky:

- Possible inability to acquire FDA clearance. The identical material is already cleared for dental use and has a safe and effective history, but the possibility still exists that we will not be able to acquire FDA clearance.

- When the product is cleared by the FDA more funding may be required to bring the product to market.

- Management team has a history of success gaining FDA clearance and loss of management could compromise likelihood of success.

- The FDA and USDA is continually inspecting the facility and any violations could delay product progress.

- The submission to the FDA usually takes a number of months to complete. We assume approximately 6 months but this could be extended if the FDA requires further testing.

- OsNovum will initially operate in the facilities of SteinerBio. Any conflict with SteinerBio could compromise OsNovum. However, because SteinerBio and OsNovum are under the same ownership and management and because SteinerBio has a long stable history, owns the facilities and has no long term debt, OsNovum has a very stable partner.

- COVID-19 can materially impact our business. It is unclear how long the COVID-19 pandemic will last and to what degree it could hurt our ability to generate revenues. For example, it could complicate our ability to procure materials and partnerships. There may be other effects stemming from this pandemic that are deleterious to our company which we have not yet considered.

- We will likely need to engage in equity, debt, or preferred stock financing in the future. Your rights and the value of your investment could be reduced because of this. Interest

on debt securities could increase costs and negatively impact operating results. In addition, if, in the future, we need to raise more equity capital from the sale of stock, institutional or other investors may negotiate terms at least as, and possibly more, favorable than the terms of your investment. Shares of our equity could be sold into any market which develops, which could adversely affect the market price.

While we have 15 years experience in the bone regeneration marketplace our limited operating history with OsNovum makes evaluating the business and future prospects difficult, and may increase the risk of your investment. We were incorporated in June 2020. To date, we have no revenues.

Our future success depends on the efforts of a small management team. The loss of services of the members of the management team may have an adverse effect on the company. There can be no assurance that we will be successful in attracting and retaining other personnel we require to successfully grow our business.

Daniel Vargas is a part-time officer. As such, it is likely that the company will not make the same progress as it would if that were not the case.

INSTRUCTION TO QUESTION 8: Avoid generalized statements and include only those factors that are unique to the issuer. Discussion should be tailored to the issuer's business and the offering and should not repeat the factors addressed in the legends set forth above. No specific number of risk factors is required to be identified.

# The Offering

## USE OF FUNDS

9. What is the purpose of this offering?

The Company intends to use the net proceeds of this offering for working capital and general corporate purposes, which includes the specific items listed in Item 10 below. While the Company expects to use the net proceeds from the Offering in the manner described above, it cannot specify with certainty the particular uses of the net proceeds that it will receive from this Offering. Accordingly, the Company will have broad discretion in using these proceeds.

10. How does the issuer intend to use the proceeds of this offering?

If we raise: $50,000

Use of Proceeds: 92.5% FDA Tests, 7.5% Wefunder fees

If we raise: $200,000

Use of Proceeds: 15% FDA Tests, 2.5% ISO Certification, 10% Regulatory Submission, 10% Legal, accounting, Funding Acquisition, 15% Capitol Improvements, 10% Production Equipment, 10% Product Delivery System, 20% Salaries, 7.5% Wefunder fees

INSTRUCTION TO QUESTION 10: An issuer must provide a reasonably detailed description of any intended use of proceeds, such that investors are provided with an adequate amount of information to understand how the offering proceeds will be used. If an issuer has identified a range of possible uses, the issuer should identify and describe each probable use and the factors the issuer may consider in allocating proceeds among the potential uses. If the issuer will accept proceeds in excess of the target offering amount, the issuer must describe the purpose, method for allocating oversubscriptions, and intended use of the excess proceeds with similar specificity. Please include all potential uses of the proceeds of the offering, including any that may apply only in the case of oversubscriptions. If you do not do so, you may later be required to amend your Form C. Wefunder is not responsible for any failure by you to describe a potential use of offering proceeds.

## DELIVERY &amp; CANCELLATIONS

11. How will the issuer complete the transaction and deliver securities to the investors?

Book Entry and Investment in the Co-Issuer. Investors will make their investments by investing in interests issued by one or more co-issuers, each of which is a special purpose vehicle ("SPV"). The SPV will invest all amounts it receives from investors in securities issued by the Company. Interests issued to investors by the SPV will be in book entry form. This means that the investor will not receive a certificate representing his or her investment. Each investment will be recorded in the books and records of the SPV. In addition, investors' interests in the investments will be recorded in each investor's "Portfolio" page on the Wefunder platform. All references in this Form C to an Investor's investment in the Company (or similar phrases) should be interpreted to include investments in a SPV.

12. How can an investor cancel an investment commitment?

NOTE: Investors may cancel an investment commitment until 48 hours prior to the deadline identified in these offering materials.

The intermediary will notify investors when the target offering amount has been met. If the issuer reaches the target offering amount prior to the deadline identified in the offering materials, it may close the offering early if it provides notice about the new offering deadline at least five business days prior to such new offering deadline (absent a material change that would require an extension of the offering and reconfirmation of the investment commitment).

If an investor does not cancel an investment commitment before the 48-hour period prior to the offering deadline, the funds will be released to the issuer upon closing of the offering and the investor will receive securities in exchange for his or her investment.

If an investor does not reconfirm his or her investment commitment after a material change is made to the offering, the investor's investment commitment will be cancelled and the committed funds will be returned.

An Investor's right to cancel. An Investor may cancel his or her investment commitment at any time until 48 hours prior to the offering deadline.

If there is a material change to the terms of the offering or the information provided to the Investor about the offering and/or the Company, the Investor will be provided notice of the change and must re-confirm his or her investment commitment within five business days of receipt of the notice. If the Investor does not reconfirm, he or she will receive notifications disclosing that the commitment was cancelled, the reason for the cancellation, and the refund amount that the investor is required to receive. If a material change occurs within five business days of the maximum number of days the offering is to remain open, the offering will be extended to allow for a period of five business days for the investor to reconfirm.

If the Investor cancels his or her investment commitment during the period when cancellation is permissible, or does not reconfirm a commitment in the case of a material change to the investment, or the offering does not close, all of the Investor's funds will be returned within five business days.

Within five business days of cancellation of an offering by

the Company, the Company will give each investor notification of the cancellation, disclose the reason for the cancellation, identify the refund amount the Investor will receive, and refund the Investor's funds.

The Company's right to cancel. The Investment Agreement you will execute with us provides the Company the right to cancel for any reason before the offering deadline.

If the sum of the investment commitments from all investors does not equal or exceed the target offering amount at the time of the offering deadline, no securities will be sold in the offering, investment commitments will be cancelled and committed funds will be returned.

# Ownership and Capital Structure

## THE OFFERING

13. Describe the terms of the securities being offered.

Priced Round: $19,532,200 pre-money valuation

See exact security attached as Appendix B, Investor Contracts

OsNovum is offering up to 5,000 shares of Series Seed Preferred stock, at a price per share of $40.00.

The campaign maximum is $200,000.00 and the campaign minimum is $50,000.00.

## Securities Issued by the SPV

Instead of issuing its securities directly to investors, the Company has decided to issue its securities to the SPV, which will then issue interests in the SPV to investors. The SPV is formed concurrently with the filing of the Form C. Given this, the SPV does not have any financials to report. The SPV is managed by Wefunder Admin, LLC and is a co-issuer with the Company of the securities being offered in this offering. The Company's use of the SPV is intended to allow investors in the SPV to achieve the same economic exposure, voting power, and ability to assert State and Federal law rights, and receive the same disclosures, as if they had invested directly in the Company. The Company's use of the SPV will not result in any additional fees being charged to investors.

The SPV has been organized and will be operated for the sole purpose of directly acquiring, holding and disposing of the Company's securities, will not borrow money and will use all of the proceeds from the sale of its securities solely to purchase a single class of securities of the Company. As a result, an investor investing in the Company through the SPV will have the same relationship to the Company's securities, in terms of number, denomination, type and rights, as if the investor invested directly in the Company.

## Voting Rights

If the securities offered by the Company and those offered by the SPV have voting rights, those voting rights may be exercised by the investor or his or her proxy. The applicable proxy is the Lead Investor, if the Proxy (described below) is in effect.

## Proxy to the Lead Investor

The SPV securities have voting rights. With respect to those voting rights, the investor and his, her, or its transferees or assignees (collectively, the "Investor"), through a power of attorney granted by Investor in the Investor Agreement, has appointed or will appoint the Lead Investor as the Investor's true and lawful proxy and attorney (the "Proxy") with the power to act alone and with full power of substitution, on behalf of the Investor to: (i) vote all securities related to the Company purchased in an offering hosted by Wefunder Portal, and (ii) execute, in connection with such voting power, any instrument or document that the Lead Investor determines is necessary and appropriate in the exercise of his or her authority. Such Proxy will be irrevocable by the Investor unless and until a successor lead investor ("Replacement Lead Investor") takes the place of the Lead Investor. Upon notice that a Replacement Lead Investor has taken the place of the Lead Investor, the Investor will have five (5) calendar days to revoke the Proxy. If the Proxy is not revoked within the 5-day time period, it shall remain in effect.

## Restriction on Transferability

The SPV securities are subject to restrictions on transfer, as set forth in the Subscription Agreement and the Limited Liability Company Agreement of Wefunder SPV, LLC, and may not be transferred without the prior approval of the Company, on behalf of the SPV.

14. Do the securities offered have voting rights?
☐ Yes

☑ No

15. Are there any limitations on any voting or other rights identified above?

See the above description of the Proxy to the Lead Investor.

16. How may the terms of the securities being offered be modified?

This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and may be amended only by a writing executed by all parties.

Pursuant to authorization in the Investor Agreement between each Investor and Wefunder Portal, Wefunder Portal is authorized to take the following actions with respect to the investment contract between the Company and an investor:

A. Wefunder Portal may amend the terms of an investment contract, provided that the amended terms are more favorable to the investor than the original terms; and
B. Wefunder Portal may reduce the amount of an investor's investment if the reason for the reduction is that the Company's offering is oversubscribed.

## RESTRICTIONS ON TRANSFER OF THE SECURITIES BEING OFFERED:

The securities being offered may not be transferred by any purchaser of such securities during the one year period beginning when the securities were issued, unless such securities are transferred:

1. to the issuer;
2. to an accredited investor;
3. as part of an offering registered with the U.S. Securities and Exchange Commission; or
4. to a member of the family of the purchaser or the equivalent, to a trust controlled by the purchaser, to a trust created for the benefit of a member of the family of the purchaser or the equivalent, or in connection with the death or divorce of the purchaser or other similar circumstance.

NOTE: The term "accredited investor" means any person who comes within any of the categories set forth in Rule 501(a) of Regulation D, or who the seller reasonably believes comes within any of such categories, at the time of the sale of the securities to that person.

The term "member of the family of the purchaser or the equivalent" includes a child, stepchild, grandchild, parent, stepparent, grandparent, spouse or spousal equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-

in-law, or sister-in-law of the purchaser, and includes adoptive relationships. The term "spousal equivalent" means a cohabitant occupying a relationship generally equivalent to that of a spouse.

## DESCRIPTION OF ISSUER'S SECURITIES

17. What other securities or classes of securities of the issuer are outstanding? Describe the material terms of any other outstanding securities or classes of securities of the issuer.

| Class of Security | Securities (or Amount) Authorized | Securities (or Amount) Outstanding | Voting Rights |
| --- | --- | --- | --- |
| Common | 500,000 | 480,000 | Yes ☑ |
| Preferred | 37,000 | 8,305 | Yes ☑ |

## Class of Security Warrants:

## Securities Reserved for Issuance upon Exercise or Conversion

Options:
Total Pool:
Issued:

Describe any other rights:

Preferred stock has a 1x liquidation preference over common stock.

18. How may the rights of the securities being offered be materially limited, diluted or qualified by the rights of any other class of security identified above?

The holders of a majority-in-interest of voting rights in the Company could limit the Investor's rights in a material way. For example, those interest holders could vote to change the terms of the agreements governing the Company's operations or cause the Company to engage in additional offerings (including potentially a public offering). These changes could result in further limitations on the voting rights the Investor will have as an owner of equity in the Company, for example by diluting those rights or limiting them to certain types of events or consents. To the extent applicable, in cases where the rights of holders of convertible debt, SAFES, or other outstanding options or warrants are exercised, or if new awards are granted under our equity compensation plans, an Investor's interests in the Company may be diluted. This means that the pro-rata portion of the Company represented by the Investor's securities will decrease, which could also diminish the Investor's voting and/or economic rights. In

addition, as discussed above, if a majority-in-interest of holders of securities with voting rights cause the Company to issue additional equity, an Investor's interest will typically also be diluted.

Based on the risk that an Investor's rights could be limited, diluted or otherwise qualified, the Investor could lose all or part of his or her investment in the securities in this offering, and may never see positive returns.

Additional risks related to the rights of other security holders are discussed below, in Question 20.

19. Are there any differences not reflected above between the securities being offered and each other class of security of the issuer?

No.

20. How could the exercise of rights held by the principal shareholders identified in Question 6 above affect the purchasers of the securities being offered?

As holders of a majority-in-interest of voting rights in the Company, the shareholders may make decisions with which the Investor disagrees, or that negatively affect the value of the Investor's securities in the Company, and the Investor will have no recourse to change these decisions. The Investor's interests may conflict with those of other investors, and there is no guarantee that the Company will develop in a way that is optimal for or advantageous to the Investor.

For example, the shareholders may change the terms of the Articles of Incorporation for the company, change the terms of securities issued by the Company, change the management of the Company, and even force out minority holders of securities. The shareholders may make changes that affect the tax treatment of the Company in ways that are unfavorable to you but favorable to them. They may also vote to engage in new offerings and/or to register certain of the Company's securities in a way that negatively affects the value of the securities the Investor owns. Other holders of securities of the Company may also have access to more information than the Investor, leaving the Investor at a disadvantage with respect to any decisions regarding the securities he or she owns. The shareholders have the right to redeem their securities at any time. Shareholders could decide to force the Company to redeem their securities at a time that is not favorable to the Investor and is damaging to the Company. Investors' exit may affect the value of the Company and/or its viability. In cases where the rights of holders of convertible debt, SAFES, or other outstanding options or warrants are exercised, or if new awards are granted under our equity

compensation plans, an Investor's interests in the Company may be diluted. This means that the pro-rata portion of the Company represented by the Investor's securities will decrease, which could also diminish the Investor's voting and/or economic rights. In addition, as discussed above, if a majority-in-interest of holders of securities with voting rights cause the Company to issue additional stock, an Investor's interest will typically also be diluted.

Based on the risks described above, the Investor could lose all or part of his or her investment in the securities in this offering, and may never see positive returns.

21. How are the securities being offered being valued? Include examples of methods for how such securities may be valued by the issuer in the future, including during subsequent corporate actions.

The offering price for the securities offered pursuant to this Form C has been determined arbitrarily by the Company, and does not necessarily bear any relationship to the Company's book value, assets, earnings or other generally accepted valuation criteria. In determining the offering price, the Company did not employ investment banking firms or other outside organizations to make an independent appraisal or evaluation. Accordingly, the offering price should not be considered to be indicative of the actual value of the securities offered hereby.

In the future, we will perform valuations of our common stock that take into account factors such as the following:

1. unrelated third party valuations of our common stock;
2. the price at which we sell other securities, such as convertible debt or preferred Stock, in light of the rights, preferences and privileges of our those securities relative to those of our common stock;
3. our results of operations, financial position and capital resources;
4. current business conditions and projections;
5. the lack of marketability of our common stock;
6. the hiring of key personnel and the experience of our management;
7. the introduction of new products;
8. the risk inherent in the development and expansion of our products;
9. our stage of development and material risks related to our business;
10. the likelihood of achieving a liquidity event, such as an initial public offering or a sale of our company given the prevailing market conditions and the nature and history of our business;
11. industry trends and competitive environment;
12. trends in consumer spending, including consumer confidence;
13. overall economic indicators, including gross domestic

product, employment, inflation and interest rates; and
14. the general economic outlook.

We will analyze factors such as those described above
using a combination of financial and market-based
methodologies to determine our business enterprise value.
For example, we may use methodologies that assume that
businesses operating in the same industry will share similar
characteristics and that the Company's value will correlate
to those characteristics, and/or methodologies that
compare transactions in similar securities issued by us that
were conducted in the market.

22. What are the risks to purchasers of the securities relating to
minority ownership in the issuer?

An Investor in the Company will likely hold a minority
position in the Company, and thus be limited as to its ability
to control or influence the governance and operations of
the Company.

The marketability and value of the Investor's interest in the
Company will depend upon many factors outside the
control of the Investor. The Company will be managed by
its officers and be governed in accordance with the
strategic direction and decision-making of its Board Of
Directors, and the Investor will have no independent right
to name or remove an officer or member of the Board Of
Directors of the Company.

Following the Investor's investment in the Company, the
Company may sell interests to additional investors, which
will dilute the percentage interest of the Investor in the
Company. The Investor may have the opportunity to
increase its investment in the Company in such a
transaction, but such opportunity cannot be assured.

The amount of additional financing needed by the
Company, if any, will depend upon the maturity and
objectives of the Company. The declining of an opportunity
or the inability of the Investor to make a follow-on
investment, or the lack of an opportunity to make such a
follow-on investment, may result in substantial dilution of
the Investor's interest in the Company.

23. What are the risks to purchasers associated with corporate
actions, including additional issuances of securities, issuer
repurchases of securities, a sale of the issuer or of assets of the
issuer or transactions with related parties?

Additional issuances of securities. Following the Investor's
investment in the Company, the Company may sell interests

to additional investors, which will dilute the percentage interest of the Investor in the Company. The Investor may have the opportunity to increase its investment in the Company in such a transaction, but such opportunity cannot be assured. The amount of additional financing needed by the Company, if any, will depend upon the maturity and objectives of the Company. The declining of an opportunity or the inability of the Investor to make a follow-on investment, or the lack of an opportunity to make such a follow-on investment, may result in substantial dilution of the Investor's interest in the Company.

**Issuer repurchases of securities.** The Company may have authority to repurchase its securities from shareholders, which may serve to decrease any liquidity in the market for such securities, decrease the percentage interests held by other similarly situated investors to the Investor, and create pressure on the Investor to sell its securities to the Company concurrently.

**A sale of the issuer or of assets of the issuer.** As a minority owner of the Company, the Investor will have limited or no ability to influence a potential sale of the Company or a substantial portion of its assets. Thus, the Investor will rely upon the executive management of the Company and the Board of Directors of the Company to manage the Company so as to maximize value for shareholders. Accordingly, the success of the Investor's investment in the Company will depend in large part upon the skill and expertise of the executive management of the Company and the Board of Directors of the Company. If the Board Of Directors of the Company authorizes a sale of all or a part of the Company, or a disposition of a substantial portion of the Company's assets, there can be no guarantee that the value received by the Investor, together with the fair market estimate of the value remaining in the Company, will be equal to or exceed the value of the Investor's initial investment in the Company.

**Transactions with related parties.** The Investor should be aware that there will be occasions when the Company may encounter potential conflicts of interest in its operations. On any issue involving conflicts of interest, the executive management and Board of Directors of the Company will be guided by their good faith judgement as to the Company's best interests. The Company may engage in transactions with affiliates, subsidiaries or other related parties, which may be on terms which are not arm's-length, but will be in all cases consistent with the duties of the management of the Company to its shareholders. By acquiring an interest in the Company, the Investor will be

deemed to have acknowledged the existence of any such actual or potential conflicts of interest and to have waived any claim with respect to any liability arising from the existence of any such conflict of interest.

24. Describe the material terms of any indebtedness of the issuer:

| Loan |  |
| --- | --- |
| Lender | Gregory Steiner |
| Issue date | 12/30/23 |
| Amount | $4,643.00 |
| Outstanding principal plus interest | $4,643.38 as of 06/09/24 |
| Interest rate | 0.0% per annum |
| Maturity date | 12/31/26 |
| Current with payments | Yes |

Loan from officer. May be repaid at some point, transferred to stock, or left as a loan.

INSTRUCTION TO QUESTION 24: name the creditor, amount owed, interest rate, maturity date, and any other material terms.

25. What other exempt offerings has the issuer conducted within the past three years?

| Offering Date | Exemption | Security Type | Amount Sold | Use of Proceeds |
| --- | --- | --- | --- | --- |
|  | Regulation | Priced | $129,559 | General operations |
|  | Crowdfunding | Round |  |  |

26. Was or is the issuer or any entities controlled by or under common control with the issuer a party to any transaction since the beginning of the issuer's last fiscal year, or any currently proposed transaction, where the amount involved exceeds five percent of the aggregate amount of capital raised by the issuer in reliance on Section 4(a)(6) of the Securities Act during the preceding 12-month period, including the amount the issuer seeks to raise in the current offering, in which any of the following persons had or is to have a direct or indirect material interest:

1. any director or officer of the issuer;
2. any person who is, as of the most recent practicable date, the beneficial owner of 20 percent or more of the issuer's outstanding voting equity securities, calculated on the basis of voting power;
3. if the issuer was incorporated or organized within the past three years, any promoter of the issuer;
4. or any immediate family member of any of the foregoing persons

☑ Yes
☐ No

For each transaction specify the person, relationship to issuer, nature of interest in transaction, and amount of interest.

| Name | Gregory Steiner |
| --- | --- |
| Amount Invested | $4,643.00 |
| Transaction type | Loan |
| Issue date | 12/30/23 |
| Outstanding principal plus interest | $4,643.38 as of 06/09/24 |
| Interest rate | 0.0% per annum |
| Maturity date | 12/31/26 |
| Current with payments | Yes |
| Relationship | Officer |

**INSTRUCTIONS TO QUESTION 26:** The term transaction includes, but is not limited to, any financial transaction, arrangement or relationship (including any indebtedness or guarantee of indebtedness) or any series of similar transactions, arrangements or relationships.

Beneficial ownership for purposes of paragraph (2) shall be determined as of a date that is no more than 120 days prior to the date of filing of this offering statement and using the same calculation described in Question 6 of this Question and Answer format.

The term "member of the family" includes any child, stepchild, grandchild, parent, stepparent, grandparent, spouse or spousal equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law of the person, and includes adoptive relationships. The term "spousal equivalent" means a cohabitant occupying a relationship generally equivalent to that of a spouse.

Compute the amount of a related party's interest in any transaction without regard to the amount of the profit or loss involved in the transaction. Where it is not practicable to state the approximate amount of the interest, disclose the approximate amount involved in the transaction.

# FINANCIAL CONDITION OF THE ISSUER

27. Does the issuer have an operating history?

☑ Yes
☐ No

28. Describe the financial condition of the issuer, including, to the extent material, liquidity, capital resources and historical results of operations.

## Management's Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes and other financial information included elsewhere in this offering. Some of the information contained in this discussion and analysis, including information regarding the strategy and plans for our business, includes forward-looking statements that involve risks and uncertainties. You should review the "Risk Factors" section for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

## Overview

We improve skeletal health to extend lifespan and increase quality of life.

OsNovum has developed the technology to regenerate bone to maintain skeletal health. Weak bones are a major reason for frailty as we age. OsNovum has the proven technology to regenerate bone but will also open clinics devoted exclusively to skeletal health and the prevention of frailty as we age.

## Milestones

OsNovum was incorporated in the State of Wyoming in June 2020.

Since then, we have:

- OsNovum founders own the patent to this technology (patents are in Dr. Gregory Steiner's name)
- Already FDA-cleared for maxillofacial use, streamlining the track to clearance in the skeleton
- Disruptive new technology for the $73B osteoporosis treatment industry
- Parent company, SteinerBio, world leader in bone

regeneration provides building and staff

- We have a clear exit strategy in place at 3 years (projections not guaranteed)
- Launch of specialty clinics using our tech, guided by world leading scientists, staffed by industry leading clinicians
- Profits will be generated by our regenerative technology, but accelerated through the OsNovum clinics

The Company is subject to risks and uncertainties common to early-stage companies. Given the Company's limited operating history, the Company cannot reliably estimate how much revenue it will receive in the future.

## Historical Results of Operations

Our company was organized in June 2020 and has limited operations upon which prospective investors may base an evaluation of its performance.

- Revenues &amp; Gross Margin. For the period ended December 31, 2024, the Company had revenues of $0 compared to the year ended December 31, 2023, when the Company had revenues of $0.
- Assets. As of December 31, 2024, the Company had total assets of $9,440, including $9,440 in cash. As of December 31, 2023, the Company had $137 in total assets, including $137 in cash.
- Net Loss. The Company has had net losses of $55,814 and net losses of $22,650 for the fiscal years ended December 31, 2024 and December 31, 2023, respectively.
- Liabilities. The Company's liabilities totaled $0 for the fiscal year ended December 31, 2024 and $4,643 for the fiscal year ended December 31, 2023.

## Liquidity &amp; Capital Resources

To date, the company has been funded with $209,255 in equity.

After the conclusion of this Offering, should we hit our minimum funding target, our projected runway is 24 months before we need to raise further capital.

We plan to use the proceeds as set forth in this Form C under "Use of Funds". We don't have any other sources of capital in the immediate future.

We will likely require additional financing in excess of the proceeds from the Offering in order to perform operations over the lifetime of the Company. Except as otherwise described in this Form C, we do not have additional sources

described in this Form C, we do not have additional sources of capital other than the proceeds from the offering. Because of the complexities and uncertainties in establishing a new business strategy, it is not possible to adequately project whether the proceeds of this offering will be sufficient to enable us to implement our strategy. This complexity and uncertainty will be increased if less than the maximum amount of securities offered in this offering is sold. The Company intends to raise additional capital in the future from investors. Although capital may be available for early-stage companies, there is no guarantee that the Company will receive any investments from investors.

## Runway &amp; Short/Mid Term Expenses

OsNovum cash in hand is $130.97, as of May 2024. Over the last three months, revenues have averaged $0/month, cost of goods sold has averaged $0/month, and operational expenses have averaged $1,000/month, for an average burn rate of $1,000 per month. Our intent is to be profitable in 24 months.

We have had no changes since the last financials and expect no changes until finding. All plans are on hold until funding.

We plan to submit to the FDA for orthopedic clearance when funding occurs. We have the submission written and consultants in place. In six months, we anticipate expenses to total $50K, and we may also receive some funding from human trials.

We will need funding for our submission to the FDA. When clearance by the FDA is accomplished we will proceed to market the product with profitability. Assuming no unforeseen obstacles, we will need a capital of $200k to achieve profitability. However, having $400k would be preferable.

Aside from Wefunder, with the submission complete along with the required testing, the primary costs have been covered. We are seeking additional funding to complete FDA clearance. The short-term burn will be covered by the CEO.

All projections in the above narrative are forward-looking and not guaranteed.

INSTRUCTIONS TO QUESTION 28: The discussion must cover each year for which financial statements are provided. For issuers with no prior

operating history, the discussion should focus on financial milestones and operational, liquidity and other challenges. For issuers with an operating history, the discussion should focus on whether historical results and cash flows are representative of what investors should expect in the future. Take into account the proceeds of the offering and any other known or pending sources of capital. Discuss how the proceeds from the offering will affect liquidity, whether receiving these funds and any other additional funds is necessary to the viability of the business, and how quickly the issuer anticipates using its available cash. Describe the other available sources of capital to the business, such as lines of credit or required contributions by shareholders. References to the issuer in this Question 28 and these instructions refer to the issuer and its predecessors, if any.

# FINANCIAL INFORMATION

29. Include financial statements covering the two most recently completed fiscal years or the period(s) since inception, if shorter:

Refer to Appendix C, Financial Statements

I, Gregory Gene Steiner, certify that:

(1) the financial statements of OsNovum included in this Form are true and complete in all material respects; and
(2) the financial information of OsNovum included in this Form reflects accurately the information reported on the tax return for OsNovum filed for the most recently completed fiscal year.

Gregory Gene Steiner
Biotech officer

# STAKEHOLDER ELIGIBILITY

30. With respect to the issuer, any predecessor of the issuer, any affiliated issuer, any director, officer, general partner or managing member of the issuer, any beneficial owner of 20 percent or more of the issuer's outstanding voting equity securities, any promoter connected with the issuer in any capacity at the time of such sale, any person that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with such sale of securities, or any general partner, director, officer or managing member of any such solicitor, prior to May 16, 2016:

(1) Has any such person been convicted, within 10 years (or five years, in the case of issuers, their predecessors and affiliated issuers) before the filing of this offering statement, of any felony or misdemeanor:

i. in connection with the purchase or sale of any security? ☐ Yes ☑ No
ii. involving the making of any false filing with the Commission? ☐ Yes ☑ No
iii. arising out of the conduct of the business of an underwriter, broker, dealer, municipal securities dealer, investment adviser, funding portal or paid solicitor of purchasers of securities? ☐ Yes ☑ No

(2) Is any such person subject to any order, judgment or decree of any court of competent jurisdiction, entered within five years before the filing of the information required by Section 4A(b) of the Securities Act that, at the time of filing of this offering statement, restrains or enjoins such person from engaging or continuing to engage in any conduct or practice:

i. in connection with the purchase or sale of any security? ☐ Yes ☑ No
ii. involving the making of any false filing with the Commission? ☐ Yes ☑ No
iii. arising out of the conduct of the business of an underwriter, broker, dealer, municipal securities dealer, investment adviser, funding portal or paid solicitor of purchasers of securities? ☐ Yes ☑ No

(3) Is any such person subject to a final order of a state securities commission (or an agency or officer of a state performing like functions); a state authority that supervises or examines banks, savings associations or credit unions; a state insurance commission (or an agency or officer of a state performing like functions); an appropriate federal banking agency; the U.S. Commodity Futures Trading Commission; or the National Credit Union Administration that:

i. at the time of the filing of this offering statement bars the person from:

A. association with an entity regulated by such commission, authority, agency or officer? ☐ Yes ☑ No
B. engaging in the business of securities, insurance or banking? ☐ Yes ☑ No
C. engaging in savings association or credit union activities? ☐ Yes ☑ No

ii. constitutes a final order based on a violation of any law or regulation that prohibits fraudulent, manipulative or deceptive conduct and for which the order was entered within the 10-year period ending on the date of the filing of this offering statement? ☐ Yes ☑ No

(4) Is any such person subject to an order of the Commission entered pursuant to Section 15(b) or 15B(c) of the Exchange Act or Section 203(e) or (f) of the Investment Advisers Act of 1940 that, at the time

200(e) or (f) of the Investment Advisers Act of 1940 that, at the time of the filing of this offering statement:

i. suspends or revokes such person's registration as a broker, dealer, municipal securities dealer, investment adviser or funding portal? ☐ Yes ☑ No
ii. places limitations on the activities, functions or operations of such person? ☐ Yes ☑ No
iii. bars such person from being associated with any entity or from participating in the offering of any penny stock? ☐ Yes ☑ No

(5) Is any such person subject to any order of the Commission entered within five years before the filing of this offering statement that, at the time of the filing of this offering statement, orders the person to cease and desist from committing or causing a violation or future violation of:

i. any scienter-based anti-fraud provision of the federal securities laws, including without limitation Section 17(a)(1) of the Securities Act, Section 10(b) of the Exchange Act, Section 15(c)(1) of the Exchange Act and Section 206(1) of the Investment Advisers Act of 1940 or any other rule or regulation thereunder? ☐ Yes ☑ No
ii. Section 5 of the Securities Act? ☐ Yes ☑ No

(6) Is any such person suspended or expelled from membership in, or suspended or barred from association with a member of, a registered national securities exchange or a registered national or affiliated securities association for any act or omission to act constituting conduct inconsistent with just and equitable principles of trade?

☐ Yes ☑ No

(7) Has any such person filed (as a registrant or issuer), or was any such person or was any such person named as an underwriter in, any registration statement or Regulation A offering statement filed with the Commission that, within five years before the filing of this offering statement, was the subject of a refusal order, stop order, or order suspending the Regulation A exemption, or is any such person, at the time of such filing, the subject of an investigation or proceeding to determine whether a stop order or suspension order should be issued?

☐ Yes ☑ No

(8) Is any such person subject to a United States Postal Service false representation order entered within five years before the filing of the information required by Section 4A(b) of the Securities Act, or is any such person, at the time of filing of this offering statement, subject to a temporary restraining order or preliminary injunction with respect to conduct alleged by the United States Postal Service to constitute a scheme or device for obtaining money or property through the mail by means of false representations?

☐ Yes ☑ No

If you would have answered "Yes" to any of these questions had

the conviction, order, judgment, decree, suspension, expulsion or bar occurred or been issued after May 16, 2016, then you are NOT eligible to rely on this exemption under Section 4(a)(6) of the Securities Act.

INSTRUCTIONS TO QUESTION 30: Final order means a written directive or declaratory statement issued by a federal or state agency, described in Rule 503(a)(3) of Regulation Crowdfunding, under applicable statutory authority that provides for notice and an opportunity for hearing, which constitutes a final disposition or action by that federal or state agency.

No matters are required to be disclosed with respect to events relating to any affiliated issuer that occurred before the affiliation arose if the affiliated entity is not (i) in control of the issuer or (ii) under common control with the issuer by a third party that was in control of the affiliated entity at the time of such events.

# OTHER MATERIAL INFORMATION

31. In addition to the information expressly required to be included in this Form, include:

- (1) any other material information presented to investors; and
- (2) such further material information, if any, as may be necessary to make the required statements, in the light of the circumstances under which they are made, not misleading.

The Lead Investor. As described above, each Investor that has entered into the Investor Agreement will grant a power of attorney to make voting decisions on behalf of that Investor to the Lead Investor (the "Proxy"). The Proxy is irrevocable unless and until a Successor Lead Investor takes the place of the Lead Investor, in which case, the Investor has a five (5) calendar day period to revoke the Proxy. Pursuant to the Proxy, the Lead Investor or his or her successor will make voting decisions and take any other actions in connection with the voting on Investors' behalf.

The Lead Investor is an experienced investor that is chosen to act in the role of Lead Investor on behalf of Investors that have a Proxy in effect. The Lead Investor will be chosen by the Company and approved by Wefunder Inc. and the identity of the initial Lead Investor will be disclosed to Investors before Investors make a final investment decision to purchase the securities related to the Company.

The Lead Investor can quit at any time or can be removed by Wefunder Inc. for cause or pursuant to a vote of investors as detailed in the Lead Investor Agreement. In the event the Lead Investor quits or is removed, the Company

will choose a Successor Lead Investor who must be approved by Wefunder Inc. The identity of the Successor Lead Investor will be disclosed to Investors, and those that have a Proxy in effect can choose to either leave such Proxy in place or revoke such Proxy during a 5-day period beginning with notice of the replacement of the Lead Investor.

The Lead Investor will not receive any compensation for his or her services to the SPV. The Lead Investor may receive compensation if, in the future, Wefunder Advisors LLC forms a fund ("Fund") for accredited investors for the purpose of investing in a non-Regulation Crowdfunding offering of the Company. In such a circumstance, the Lead Investor may act as a portfolio manager for that Fund (and as a supervised person of Wefunder Advisors) and may be compensated through that role.

Although the Lead Investor may act in multiple roles with respect to the Company's offerings and may potentially be compensated for some of its services, the Lead Investor's goal is to maximize the value of the Company and therefore maximize the value of securities issued by or related to the Company. As a result, the Lead Investor's interests should always be aligned with those of Investors. It is, however, possible that in some limited circumstances the Lead Investor's interests could diverge from the interests of Investors, as discussed in section 8 above.

Investors that wish to purchase securities related to the Company through Wefunder Portal must agree to give the Proxy described above to the Lead Investor, provided that if the Lead Investor is replaced, the Investor will have a 5-day period during which he or she may revoke the Proxy. If the Proxy is not revoked during this 5-day period, it will remain in effect.

Tax Filings. In order to complete necessary tax filings, the SPV is required to include information about each investor who holds an interest in the SPV, including each investor's taxpayer identification number ("TIN") (e.g., social security number or employer identification number). To the extent they have not already done so, each investor will be required to provide their TIN within the earlier of (i) two (2) years of making their investment or (ii) twenty (20) days prior to the date of any distribution from the SPV. If an investor does not provide their TIN within this time, the SPV reserves the right to withhold from any proceeds otherwise payable to the Investor an amount necessary for the SPV to satisfy its tax withholding obligations as well as the SPV's reasonable estimation of any penalties that may be charged by the IRS or other relevant authority as a

be charged by the IRS or other relevant authority as a result of the investor's failure to provide their TIN. If applicable, the Company may also be required to pay Wefunder certain fees for the preparation of tax filings. Such fees and the Company's obligation to deliver required tax documents are further specified in the related Tax Services Agreement ("TSA").

Investors should carefully review the terms of the SPV Subscription Agreement for additional information about tax filings.

Potential Dissolution of the SPV. The Company has agreed that it will pay an administrative fee and / or certain tax fees to Wefunder, in addition to delivering required tax information in the manner prescribed by the TSA, where applicable. Failure to pay such fees or provide Wefunder with required tax information could result in the dissolution of the SPV (an "SPV Dissolution Event"). Subsequent to an SPV Dissolution Event, the securities held by the SPV would be distributed directly and proportionally to the individual investors. This could create administrative complexities, as investors would need to manage the securities themselves rather than having them held and administered by the SPV. Additionally, the unplanned distribution of securities may not align with investors' intended investment strategy or asset allocation.

Upon an SPV Dissolution Event, the Investor hereby consents to and agrees to accept direct assignment of the SPV's rights and obligations under any investment agreements between the SPV and the Company that is located in the Form C or C/A offering materials. The Investor acknowledges they will be bound by all terms and conditions of such agreements as if they were an original party thereto.

INSTRUCTIONS TO QUESTION 30: If information is presented to investors in a format, media or other means not able to be reflected in text or portable document format, the issuer should include:

(a) a description of the material content of such information;
(b) a description of the format in which such disclosure is presented; and
(c) in the case of disclosure in video, audio or other dynamic media or format, a transcript or description of such disclosure.

# ONGOING REPORTING

32. The issuer will file a report electronically with the Securities &amp; Exchange Commission annually and post the report on its website, no later than:

120 days after the end of each fiscal year covered by the report.

33. Once posted, the annual report may be found on the issuer's website at:

https://www.OsNovum.com/invest

The issuer must continue to comply with the ongoing reporting requirements until:

1. the issuer is required to file reports under Exchange Act Sections 13(a) or 15(d);
2. the issuer has filed at least one annual report and has fewer than 300 holders of record;
3. the issuer has filed at least three annual reports and has total assets that do not exceed $10 million;
4. the issuer or another party purchases or repurchases all of the securities issued pursuant to Section 4(a) (6), including any payment in full of debt securities or any complete redemption of redeemable securities; or the issuer liquidates or dissolves in accordance with state law.

## APPENDICES

- **Appendix A: Business Description &amp; Plan**
- **Appendix B: Investor Contracts**
- SPV Subscription Agreement
- Osnovum Subscription Agreement 2025
- **Appendix C: Financial Statements**
- Financials 1
- Financials 2
- Financials 3
- Financials 4
- Financials 5
- **Appendix D: Director &amp; Officer Work History**
- Daniel Vargas
- Gregory Gene Steiner
- Roslynn Lilian Steiner

Appendix E: Supporting Documents

# Signatures

Intentional misstatements or omissions of facts constitute federal criminal violations. See 18 U.S.C. 1001.

The issuer certifies that it has established means to keep accurate records of the holders of the securities it would offer and sell through the intermediary's platform.

The following documents will be filed with the SEC:

Cover Page XML

Offering Statement (this page)

Appendix A: Business Description &amp; Plan

Appendix B: Investor Contracts

SPV Subscription Agreement

Osnovum Subscription Agreement 2025

Appendix C: Financial Statements

Financials 1

Financials 2

Financials 3

Financials 4

Financials 5

Appendix D: Director &amp; Officer Work History

Daniel Vargas

Gregory Gene Steiner

Roslynn Lilian Steiner

Appendix E: Supporting Documents

Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100 et seq.), the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form C and has duly caused this Form to be signed on its behalf by the duly authorized undersigned.

OsNovum

By

Gregory Steiner

Chief Science Officer

Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100 et seq.), this Form C and Transfer Agent Agreement has been signed by the following persons in the capacities and on the dates indicated.

Gregory Steiner

Chief Science Officer

6/18/2025

Roslynn Steiner

President

6/18/2025

Daniel Vargas

VP of Marketing

6/18/2025

The Form C must be signed by the issuer, its principal executive officer or officers, its principal financial officer, its controller or principal accounting officer and at least a majority of the board of directors or persons performing similar functions.

I authorize Wefunder Portal to submit a Form C to the SEC based on the information I provided through this online form and my company’s Wefunder profile.

As an authorized representative of the company, I appoint Wefunder Portal as the company’s true and lawful representative and attorney-in-fact, in the company’s name, place and stead to make, execute, sign, acknowledge, swear to and file a Form C on the company’s behalf. This power of attorney is coupled with an interest and is irrevocable. The company hereby waives any and all defenses that may be available to contest, negate or disaffirm the actions of Wefunder Portal taken in good faith under or in reliance upon this power of attorney.

**Attachment 2:** `document_2.pdf`

![img-0.jpeg](img-0.jpeg)

## INVEST IN OSNOVUM

Revolutionizing the $25B osteoporosis industry with a novel regenerative solution for weak bones

osnovum.com Henderson, NV in ![img-1.jpeg](img-1.jpeg)

## Highlights

1. Patented bone-regenerating technology ready to disrupt the $25B osteoporosis market.

2. FDA-cleared for maxillofacial bone; streamlined path to clearance for full skeletal applications.

3. Thousands of successful patients treated with regenerative bone solutions using proven materials.
4. Clear exit strategy within 3 years, with potential acquisition by industry leaders.
5. Novel alternative to osteoporosis drugs with no systemic side effects-patients demand better.
6. Innovative specialty clinics will deliver localized treatment with scalable patient care models.

## Featured Investor

2. Ron Ask
Invested $71,001 ☑
Follow

&gt; “As an experienced dentist, we have been using the same bone graft materials in the jaws for over 15 years. I am excited to see this same technology used to regenerate bone from loss due to osteoporosis. This will greatly help to change the lives of millions of people. The current treatment for osteoporosis kills bone, OsNovum graft material builds strong bone and can be placed locally right were the bone loss occurs. This revolutionary treatment does not kill osteoclasts that are needed to create osteoblasts, which traditional treatments does.”

## Our Team

Roslynn L Steiner CEO and President
Led SteinerBio’s rise as an innovative leader in maxillofacial bone grafts with science-based, patient-focused solutions

I have devoted my career to bone regeneration. There is nothing that is more exciting to

I have devoted my career to bone regeneration. There is nothing that is more exciting to study and nothing more satisfying to watch someone regain their health!

![img-2.jpeg](img-2.jpeg)

## Gregory Steiner Chief Science Officer

Discovered and patented a breakthrough molecule that drives bone regeneration in a localized area.

![img-3.jpeg](img-3.jpeg)

## Daniel Vargas VP Marketing of SteinerBio and OsNovum

Developed and executed the marketing strategy that positioned SteinerBio as a biotech leader.

## Future-Proofing Bones: A New Standard in Skeletal Health

## OsNovum

REGENERATIVE SOLUTIONS FOR SKELETAL HEALTH

At OsNovum, we are pioneering a breakthrough solution for osteoporosis and osteopenia-conditions that silently rob millions of their mobility, independence, and quality of life. Our mission is simple but powerful: to transform bone health through innovative regenerative technology and deliver lasting hope for those suffering from these debilitating diseases.

# THE PROBLEM

Osteoporosis, often called the "silent thief," affects over 200 million people worldwide and causes 8.9 million fractures annually. Current treatments come with severe side effects, leaving patients with limited and often difficult decisions to make. We believe they deserve better.

# OUR SOLUTION

Building on decades of research, our FDA-cleared technology goes beyond treating symptoms-it regenerates poorly mineralized bone, transforming it into dense, healthy vital bone. Our patented molecule works by targeting the patient's own bone-growing cells (osteoblasts), stimulating natural regeneration without the risks of systemic side effects.

# TECHNOLOGY &amp; PROCESS

- Localized Application: Our regenerative material is applied locally to areas of low bone density, ensuring targeted and efficient treatment.
- Natural Bone Regeneration: The patient's osteoblasts absorb our patented compound, migrate into surrounding tissue, and rebuild bone with increased mineral density and vitality.
- A New Standard of Care: Our long-term goal is to establish specialized clinics where patients can access skeletal treatments based on the latest scientific knowledge and advancements in bone health.

# MARKET OPPORTUNITY

The global osteoporosis market is projected to reach $25.3 billion by 2025, presenting a major opportunity for disruptive innovation. OsNovum is uniquely positioned to capture market share by offering a novel, science-based solution to an underserved population. We plan to launch in key U.S. markets and strategically expand to meet international demand.

# TRACTION &amp; MILESTONES

Our maxillofacial technology has already been FDA-cleared and successfully used to regenerate maxillofacial bone in thousands of patients over the past decade. We are now adapting this proven technology for skeletal applications. With regulatory experts and strategic partners on board, we're on track to submit a De Novo application-an essential milestone on our path to market entry.

# OSNOVUM TEAM

At OsNovum, our team includes seasoned industry leaders, including a former FDA assistant director and world-class scientists, who bring decades of experience in biotechnology and regulatory compliance. This expertise ensures that every step of our journey-research, development, and market entry-is executed with precision and strategy.

We are committed to transforming bone health. Your investment can help

accelerate the delivery of this groundbreaking solution to millions of patients in need. Together, we can reshape the future of osteoporosis care.

# INVESTMENT OPPORTUNITY

Invest in OsNovum and be part of the next major breakthrough in healthcare innovation. With our proven regenerative technology and a clear path to FDA approval, we're on the brink of revolutionizing osteoporosis care.

Help us create a future where bone loss is no longer a life-altering diagnosis. Join us in turning innovation into impact and redefining the standard of care in bone health.

# OSNOVUM ORIGINS

## From Dental Success to Skeletal Innovation

In 2016, SteinerBio began adapting its proven regenerative technology-originally FDA-cleared for maxillofacial applications-to treat failing skeletal bone. While this material had successfully restored bone health in thousands of dental patients, applying it to the skeleton required a separate regulatory pathway. Thus, OsNovum was born to pioneer this transition and bring our innovative bone regeneration technology to patients suffering from osteoporosis and other skeletal diseases.

Regulatory Journey: Navigating Uncharted Territory

We initially pursued a 510(k) application, using SteinerBio’s FDA-cleared regenerative material as predicate technology. However, the FDA’s Skeletal Device division had never encountered a device that actively stimulates bone growth. As a result, they were navigating uncharted regulatory territory and ultimately ruled out the 510(k) option.

The core issue: the Skeletal Device division does not recognize maxillofacial materials as predicates for skeletal use. With a PMA submission ruled out due to impracticality, we found the optimal path forward: **De Novo submission**.

## Why De Novo?

De Novo submissions are designed for unique devices that present moderate risk and have no prior classification history. OsNovum’s technology fits these criteria perfectly. Shortly after receiving our Q-submission response from the FDA, we were approached by a former FDA principal who had worked on our original submissions. Now a consultant, this expert offered to help guide our De Novo application. Contracting their consulting firm was a monumental step in advancing our regulatory process.

## Next Steps: Securing Clearance and Funding

To succeed with our De Novo application, we need to raise funds to cover critical expenses:

- $30,000 FDA submission fee for the De Novo request
- Consulting fees for experts guiding us through the process
- Additional laboratory testing beyond what we’ve already completed, if required by the FDA

With this team and plan in place, we’re optimistic about achieving clearance without requiring human clinical trials. However, we know that the FDA never grants approval without demanding thorough validation.

## Forward Momentum: Moving Full Speed Ahead

Regardless of the challenges or amount raised, OsNovum remains committed

to moving forward at full speed. Our mission to revolutionize bone health is too important to slow down. Together, we can create a future where skeletal diseases are treated with precision, innovation, and success.

# Downloads

- OsNovum Pitch Deck 2025.pdf

**Attachment 3:** `document_3.pdf`

# PURCHASE AND SALE AGREEMENT OF SERIES SEED PREFERRED STOCK

This Series Seed Preferred Stock Purchase Agreement (this "Agreement"), is made as of [EFFECTIVE DATE], by and among OsNovum, a Wyoming corporation (the "Company"), and the investors that execute original or counterpart signature pages to this Agreement (each a "Purchaser" and collectively the "Purchasers").

## Recitals:

WHEREAS, The Company is conducting an offering (the "Offering") under Section 4(a)(6) of the Securities Act of 1933, as amended (the "Securities Act") and Regulation Crowdfunding promulgated thereunder. This Offering is made pursuant to the Form C, as amended, filed by the Company with the SEC (the "Form C") and the Offering Statement, which is included therein (the "Offering Statement"). The Company is offering to both accredited and non-accredited investors up to $200,000.00 of Preferred Shares (each "Stock" or "Share" and, collectively, the "Shares" or "Stocks") at a price of $40 per Share for 5,000 Shares sold in the Offering (the applicable purchase price paid by the undersigned being the "Purchase Price"). The Shares have the relative rights, preferences, privileges, and priorities specified in the Amended and Restated Articles of Incorporation of the Company. The minimum amount or target amount to be raised in the Offering is $50,000 (the "Target Offering Amount") and the maximum amount to be raised in the offering is $200,000.00 (the "Maximum Offering Amount"). If the Offering is oversubscribed beyond the Target Offering Amount, the Company will sell Stocks on a basis to be determined by the Company's management.

WHEREAS, The Company is offering the Shares to prospective investors through the Wefunder crowdfunding portal (the "Portal"). The Portal is registered with the Securities and Exchange Commission (the "SEC"), as a funding portal and is a funding portal member of the Financial Industry Regulatory Authority. The Company will pay the Portal a commission equal to 7.5% of gross monies raised in the Offering. Investors should carefully review the Form C and the accompanying Offering Statement, which are available on the website of the Portal at www.wefunder.com.

NOW, THEREFORE, for good and valuable consideration, the receipt of which is acknowledged hereby, the undersigned agrees as follows:

## Section 1: Definitions

Capitalized terms shall have the meaning set forth in this Agreement. Capitalized terms not otherwise defined shall have their ordinary meaning.

## Section 2: Authorization and Sale of Series Seed Preferred Stock

2.2 Authorization. The Company will, prior to the Initial Closing (as defined below), authorize the sale and issuance of up to 37,000 shares of its Series Seed Convertible Preferred Stock (the "Preferred Shares"). The Preferred Shares shall have the rights, privileges, preferences, and restrictions as set forth in the Articles of Incorporation. Furthermore, the Company will authorize the creation of 37,000 shares

Common Stock which shall be reserved for issuance upon conversion of the Preferred Shares (the "Conversion Stock").

2.3 Sale and Issuance of Preferred Shares. Subject to the terms and conditions of this Agreement, each Purchaser agrees to purchase at the Closing, and the Company agrees to sell and issue to each Purchaser at the Closing that number of Preferred Shares, rounded down to the nearest whole share, equal to the amount received by the escrow agent established by the Portal (the "Escrow Agent"), divided by the Purchase Price and/or the number of Preferred Shares the Purchaser agreed to purchase when executing this Agreement (the Purchaser's "Subscription").

2.4 Subscription and Payment. Payment for the Preferred Shares shall be received from each Purchaser by ACH electronic transfer, wire transfer of immediately available funds, or other means approved by the Company, in the full amount the Purchaser agreed to pay upon execution of this Agreement. Tendered funds will be received by the Escrow Agent, and shall remain in escrow until the Target Offering Amount is raised. In the event that the Target Investment Amount has not been raised by the date determined by the Company, any money tendered by Purchasers will be promptly returned by the Escrow Agent.

2.5 Acceptance of Purchaser's Subscription. Each Purchaser's subscription may be accepted or rejected in whole or in part, at any time prior to a Closing (defined below), by the Company in its sole discretion. Additionally, the Company, in its sole discretion, may allocate to a Purchaser only a portion of the number of Preferred Shares the Purchaser has subscribed for. The Company will notify Purchaser whether this subscription is accepted (whether in whole or in part) or rejected. If a Purchaser's subscription is rejected, Purchaser's payment (or portion thereof if partially rejected) will be returned to Purchaser without interest. Thereafter, all of the Company's and Purchaser's obligations hereunder relating to the rejected portion of the subscription shall terminate.

# Section 3: Closing and Delivery

## 3.1 Closing.

A. The Initial Closing. The initial purchase and sale of the shares of Series Seed Preferred Stock hereunder shall take place remotely via the exchange of documents and signatures on the Agreement Date or the subsequent date on which one or more Purchasers execute on counterpart signature pages to this Agreement and deliver the Purchase Price to the Company (which date is referred to herein as the "Initial Closing").

B. Additional Closings. If less than all of the Shares are sold and issued at the Initial Closing, then, subject to the terms and conditions of this Agreement, the Company may, without the consent of the holders of Preferred Shares, sell and issue Preferred Shares at one or more subsequent Closings (each, an "Additional Closing"), within 90 days after the Initial Closing. The Company may sell and issue the number of Preferred Shares up to the balance of the unissued Preferred Shares to such persons or entities as may be approved by the Company.

Any sale and issuance in an Additional Closing shall be on the same terms and conditions as those contained herein, and such persons or entities shall, upon execution and delivery of counterpart signature pages to this Agreement, become parties to, and be bound by, this Agreement, without need for an amendment to any of the Agreements, and shall have the rights and obligations hereunder and thereunder, in each case as of the date of the applicable Additional Closing. Each Additional Closing shall take place at such date, time and place, and/or manner as shall be approved by the Company.

### 3.2 Delivery.

Upon each successful Closing, the Escrow Agent shall release each Purchaser’s funds to the Company, provided the Total Series Seed Investment Amount has been met. Each Purchaser shall receive a notice (via electronic mail) of a digital entry of the number of the Shares owned by Purchaser which shall be reflected on the books and records of the Company. Such books and records shall bear a notation that the Preferred Shares were sold in reliance upon Regulation CF of the JOBS Act of 2012.

## Section 4: Representations and Warranties of the Company

### 4.1 General.

The Company hereby represents and warrants to each Purchaser that the following representations are true and complete as of the Effective Date, except as otherwise indicated.

### 4.2 Organization, Good Standing, Corporate Power, and Qualification.

The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Wyoming and has all corporate power and corporate authority required (a) to carry on its business as presently conducted and as presently proposed to be conducted and (b) to execute, deliver and perform its obligations under this Agreement. The Company is duly qualified to transact business as a foreign corporation and is in good standing under the laws of each jurisdiction in which the failure to so qualify or be in good standing would have a material adverse effect on the business, assets (including intangible assets), liabilities, financial condition, property, or results of operations of the Company.

### 4.3 Capitalization.

The authorized capital of the Company consists, immediately prior to the Agreement Date (unless otherwise noted), of the following:

**A. Common Stock.** The number of shares of Common Stock of the Company (the “Common Stock”) equal to 500,000, with a par value of $50, of which 480,000 shares are issued and outstanding. 37,000 shares have been authorized and are issuable upon conversion of the Preferred Shares. The Company has not authorized or reserved any Common Stock to employees, consultants, or directors.

All of the outstanding shares of Common Stock are duly authorized, validly issued, fully paid and nonassessable, and were issued in material compliance with all applicable federal and state securities laws.

**B. Preferred Stock.** The number of Preferred Shares authorized by the company is 37,000 of which 8,305 is issued and outstanding immediately prior to the Initial Closing.

The shares of Series Seed Preferred Stock will be duly authorized, validly issued, fully paid, and nonassessable when issued, sold, and delivered in accordance with the terms and for the consideration set

forth in this Agreement. Furthermore, they will be issued in compliance with all applicable federal and state securities laws.

The Preferred Shares, when issued, will be subject to restrictions on transfer under this Agreement, applicable state and federal securities laws, and liens or encumbrances created by or imposed by a Purchaser.

## C. No Other Outstanding Securities

Except as otherwise provided in this Agreement,

there are no outstanding preemptive rights, options, warrants, conversion privileges or rights (including but not limited to rights of first refusal or similar rights), orally or in writing, to purchase or acquire any securities from the Company including, without limitation, any shares of Common Stock, or Preferred Stock, or any securities convertible into or exchangeable or exercisable for shares of Common Stock or Preferred Stock, except for (1) the conversion privileges of the Series Seed Preferred Stock pursuant to the terms of the Restated Articles, and (2) the securities and rights thereof described in this Agreement including preemptive rights.

### 4.4 Subsidiaries

The Company does not currently own or control, directly or indirectly, any interest in any other corporation, partnership, trust, joint venture, limited liability company, association, or other business entity. The Company is not a participant in any joint venture, partnership, or similar arrangement.

### 4.5 Authorization

All corporate action has been taken or will be taken prior to the applicable Closing, on the part of the Board and Purchasers that is necessary for the authorization, execution, and delivery of this Agreement by the Company, and the performance by the Company of the obligations to be performed by the Company as of the date hereof under this Agreement.

This Agreement, when executed and delivered by the Company, shall constitute the valid and legally binding obligation of the Company, enforceable against the Company in accordance with its terms.

Notwithstanding the foregoing, this Agreement shall not be valid and legally binding to the extent it is (a) limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of creditors' rights generally, or (b) is limited by-laws relating to the availability of specific performance, injunctive relief, or other equitable remedies.

### 4.6 Litigation

There is no pending action, suit, proceeding, arbitration, mediation, complaint, claim, charge or investigation before any court, arbitrator, mediator or governmental body or, to the Company's knowledge, currently threatened in writing (a) against the Company or (b) against any consultant, officer, director or key employee of the Company arising out of his or her consulting, employment or board relationship with the Company or that could otherwise materially impact the Company.

### 4.7 Intellectual Property

The Company owns or possesses sufficient legal rights to all Intellectual Property (as defined below) that is necessary to the conduct of the Company's business as now conducted

and as presently proposed to be conducted (the “Company Intellectual Property”) without any violation or infringement of the rights of others (including infringements on third-party patents, patent applications, trademarks, trademark applications, service marks, or service mark applications, without any violation or infringement known to the Company).

No product or service marketed or sold (or proposed to be marketed or sold) by the Company violates or will violate any license nor will it infringe any rights to any Intellectual Property of any other party, except that with respect to third-party patents, patent applications, trademarks, trademark applications, service marks, or service mark applications the foregoing representation is made to the Company’s knowledge only.

Other than with respect to commercially available software products under standard end-user object code license agreements, there is no outstanding option, license, agreement, claim, encumbrance or shared ownership interest of any kind relating to the Company Intellectual Property, nor is the Company bound by or a party to any options, licenses or agreements of any kind with respect to the Intellectual Property of any other person. The Company has not received any written communications alleging that the Company has violated or, by conducting its business, would violate any of the Intellectual Property of any other person.

For purposes of Section 3.8, Intellectual Property means patents, patent applications, trademarks, trademark applications, service marks, trade names, copyrights, trade secrets, licenses, domain names, mask works, information, and proprietary rights and processes.

## 4.8 Employee and Consultant Matters

Each current and former employee, consultant, and officer of the Company has executed an agreement with the Company regarding confidentiality and proprietary information substantially in the form or forms made available to the Purchasers or delivered to the counsel for the Purchasers. No current or former employee or consultant has excluded any work or invention from his or her assignment of inventions. To the Company’s knowledge, no such employees or consultants are in violation thereof. To the Company’s knowledge, none of its employees is obligated under any judgment, decree, contract, covenant or agreement that would materially interfere with such employee’s ability to promote the interest of the Company or that would interfere with such employee’s ability to promote the interests of the Company or that would conflict with the Company’s business. To the Company’s knowledge, all individuals who have purchased unvested shares of the Company’s Common Stock have timely filed elections under Section 83(b) of the Internal Revenue Code of 1986, as amended.

## 4.9 Compliance with Other Instruments

The Company is not in violation or default (a) of any provisions of the Restated Articles, or the Company’s bylaws, (b) of any judgment, order, writ or decree of any court or governmental entity, (c) of any agreement, instrument, contract, lease, note, indenture, mortgage or purchase order to which it is a party that is required to be listed on the Disclosure Schedule, or, (d) to its knowledge, of any provision of federal or state statute, rule or regulation materially applicable to the Company.

The execution, delivery, and performance of this Agreement and the consummation of the transactions contemplated by this Agreement will not, to the Company's knowledge, result in any such violation or default, or constitute, with or without the passage of time and giving of notice, either (i) a default under any such judgment, order, writ, decree, agreement, instrument, contract, lease, note, indenture, mortgage or purchase order or (ii) an event which results in the creation of any lien, charge or encumbrance upon any assets of the Company or the suspension, revocation, forfeiture, or nonrenewal of any material permit or licenses applicable to the Company.

## 4.10 Title to Property and Assets

The Company owns its properties and assets free and clear of all mortgages, deeds of trust, liens, encumbrances and security interests except for statutory liens for the payment of current taxes that are not yet delinquent and liens, encumbrances, and security interests which arise in the ordinary course of business and which do not affect material properties and assets of the Company. With respect to the property and assets it leases, the Company is in material compliance with each such lease.

## 4.11 Agreements

Except for this Agreement, there are no agreements, understandings, instruments, contracts or proposed transactions to which the Company is a party that involve (a) obligations (contingent or otherwise) of, or payments to, the Company in excess of $50,000, (b) the license of any Intellectual Property to or from the Company other than licenses with respect to commercially available software products under standard end-user object code license agreements or standard customer terms of service and privacy policies for Internet sites, (c) the grant of rights to manufacture, produce, assemble, license, market, or sell its products to any other person, or that limit the Company's exclusive right to develop, manufacture, assemble, distribute, market or sell its products, or (d) indemnification by the Company with respect to infringements of proprietary rights other than the standard customer or channel agreements (each, a "Material Agreement"). The Company is not in material breach of any Material Agreement. Each Material Agreement is in full force and effect and is enforceable by the Company in accordance with its respective terms, except as may be limited by (i) applicable bankruptcy, insolvency, reorganization or others laws of general application relating to or affecting the enforcement of creditors' rights generally, or (ii) the effect of rules of law governing the availability of equitable remedies.

## 4.12 Liabilities

The Company has no liabilities or obligations, contingent or otherwise, in excess of $25,000 individually or $100,000 in the aggregate.

## Section 5: Covenants of the Company

### 5.1 Basic Financial Information

The Company shall furnish or make available to each Purchaser that requests such information and/or to any entity that requires such information pursuant to its organizational documents when available (a) annual unaudited financial statements for each fiscal year of the Company, including an unaudited balance sheet as of the end of such fiscal year, an unaudited income statement, and an unaudited statement of cash flows, all prepared in accordance with generally accepted accounting principles and practices; and (b) quarterly unaudited financial statements for each fiscal quarter of the Company (except the last quarter of the Company's fiscal year), including an unaudited balance sheet as of the end of such fiscal quarter, an unaudited income statement, and an unaudited statement of cash flows, all prepared in accordance with generally accepted accounting principles.

5.2 Confidentiality. Notwithstanding anything in this Agreement to the contrary, no Purchaser by reason of this Agreement shall have access to any trade secrets, information regarding the technology or methods used in product development, or otherwise confidential information of the Company. The Company shall not be required to comply with any information rights of any Purchaser whom the Company reasonably determines to be a competitor or an officer, employee, director, or holder of ten percent (10%) or more of a competitor. Each Purchaser shall keep confidential and shall not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement other than to any of the Purchaser’s attorneys, accountants, consultants, and other professionals, to the extent necessary to obtain

their services in connection with monitoring the Purchaser’s investment in the Company.

5.3 Inspection Rights. A “Major Purchaser” who holds at least 10% of all issued and outstanding Preferred Shares will have the right to examine its financial account, and records and to discuss the Company’s affairs, finances and accounts with its officers, all at such reasonable times as may be requested by each Purchaser provided the Purchaser gives the company written notice of the request at least 5 business days before the date on which they wish to inspect and copy.

5.4 Reservation of Common Stock. The Company shall at all times reserve and keep available, solely for issuance and delivery upon the conversion of the Preferred Shares, all Common Stock issuable from time to time upon conversion of that number of Preferred Shares equal to the Total Shares Authorized for Sale, regardless of whether or not all such shares have been issued at such time.

## Section 6: Representations, Warranties, and Covenants of the Purchasers

Each Purchaser hereby represents and warrants to the Company, severally and not jointly the following:

6.1 Authorization. The Purchaser has full power and authority to enter into this Agreement. This Agreement, when executed and delivered by the Purchaser, will constitute a valid and legally binding obligation of the Purchaser, enforceable in accordance with their terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, and any other laws of general application relating to or affecting the enforcement of creditors’ rights generally, or (b) the effect of rules of law governing the availability of equitable remedies.

6.2 Purchase Entirely for Own Account. The Purchaser represents that the shares of Preferred Share the Purchaser will acquire will be acquired for investment for the Purchaser’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof. The Purchaser hereby confirms that he/she/it has no present intention of selling, granting any participation in, or otherwise distributing the Preferred Shares. By executing this Agreement, the Purchaser further represents that the Purchaser does not presently have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person or to any third person, with respect to any of the shares of Series Seed Preferred Stock. The Purchaser has not been formed for the specific purpose of acquiring these Preferred Shares.

6.3 Disclosure of Information. The Purchaser has had an opportunity to discuss the Company’s business, management, financial affairs, and the terms and conditions of the offering of the shares of Series Seed Preferred Stock with the Company’s management. Nothing in this Section 4, including the foregoing sentence, limits or modifies the representations and warranties of the Company in Section 4 of this Agreement or the right of the Purchasers to rely thereon.

6.4 Restricted Securities. The Purchaser understands the Company is relying on an exemption from registering the offer and sale of these Preferred Shares under the Securities Act of 1933. The Purchaser understands that the Shares are “restricted securities” under applicable federal and state securities laws and that, pursuant to these laws, shares issued through Regulation CF have a one-year restriction on transfer from the date of purchase (except to certain qualified parties as specified under Section 4(a)(6) of the Act), after which they become freely transferable.

The Purchaser acknowledges that the Company has no obligation to register or qualify the Preferred Shares, or the Common Stock into which it may be converted, for resale prior to the one-year limitation.

6.5 No Public Market. The Purchaser understands that no public market now exists for the shares of Preferred Shares and that the Company has made no assurances that a public market will ever exist for them.

6.6 Legends. The Purchaser understands that the shares of Series Seed Preferred Stock and any securities issued in respect of or exchange for the shares of Series Seed Preferred Stock, may bear any one or more of the following legends: (a) any legend set forth in, or required by, this Agreement; (b) any legend required by the securities laws of any state to the extent such laws are applicable to the shares of Series Seed Preferred Stock represented by the certificate so legend; and (c) the following legend:

THE SHARES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT IN COMPLIANCE WITH THE ACT. FOR ONE YEAR FROM THE DATE OF THIS INSTRUMENT, SECURITIES SOLD IN RELIANCE ON REGULATION CROWDFUNDING UNDER THE ACT MAY ONLY BE TRANSFERRED TO THE COMPANY, TO AN “ACCREDITED INVESTOR” WITHIN THE MEANING OF RULE 501 OF REGULATION D UNDER THE ACT, AS PART OF AN OFFERING REGISTERED UNDER THE SECURITIES ACT WITH THE SEC, OR TO MEMBER OF INVESTOR’S FAMILY OR THE EQUIVALENT, TO A TRUST CONTROLLED BY THE INVESTOR, TO A TRUST CREATED FOR THE BENEFIT OF A MEMBER OF THE FAMILY OF THE INVESTOR OR EQUIVALENT, OR IN CONNECTION WITH THE DEATH OR DIVORCE OF THE INVESTOR OR OTHER SIMILAR CIRCUMSTANCE. THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SEC, ANY STATE SECURITIES COMMISSION OR OTHER REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON THE MERITS OF THIS OFFERING OR THE ADEQUACY OR ACCURACY OF THE SUBSCRIPTION AGREEMENT OR ANY OTHER

# MATERIALS OR INFORMATION MADE AVAILABLE TO INVESTOR IN CONNECTION WITH THIS OFFERING. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL.

6.7 Purchaser Investment Limits. As set forth under Regulation Crowdfunding (“Regulation CF”), if the Purchaser is not an accredited investor, then the Purchaser represents that they have not invested, in the aggregate, over $124,000 in Regulation CF offerings over the previous 12 months, and further represents that either:

A. Purchaser’s net worth or annual income is less than $124,000, and that the amount it is investing pursuant to this Agreement, is either the greater of (1) $2,500 across all securities offered under Regulation CF over the previous 12 months or (2) 5% of the greater of their annual income or net worth across all securities offered under Regulation CF over the previous 12 months; or

B. Both Purchaser’s net worth and annual income are more than $124,000, and that the amount it is investing pursuant to this Agreement, is the greater of (1) 10% of their annual income across all securities offered under Regulation CF over the previous 12 months, or (2) 10% of their net worth across all securities offered under Regulation CF over the previous 12 months.

6.8 Exculpation Among Purchasers. The Purchaser acknowledges that it is not relying upon any person, other than the Company and its officers and directors, in making its investment or decision to invest in the Company. The Purchaser agrees that neither any Purchaser nor the respective controlling persons, officers, directors, partners, agents, or employees of any Purchaser shall be liable to any other Purchaser for any action heretofore taken or omitted to be taken by any of them in connection with the purchase of the shares of Series Seed Preferred Stock.

6.9 Residence. The Purchaser represents that the Purchaser is a resident of the United States. If the Purchaser is not a resident of the United States, such Purchaser hereby agrees to make such additional representations and warranties relating to such Purchaser’s status as a non-United States resident as reasonably may be requested by the Company and to execute and deliver such documents or agreements as reasonably may be requested by the Company relating thereto as a condition to the purchase and sale of any shares of Series Seed Preferred Stock by such Purchaser.

## Section 7: Restrictions On Transfer

7.1 Restriction on Transfer. Each person owning of record shares of Common Stock of the Company issued or issuable pursuant to the conversion of the Preferred Shares and any shares of Common Stock of the Company issued as a dividend or other distribution with respect thereto or in exchange therefor or in replacement thereof (collectively, the “Securities”) or any assignee of record of Securities (each such person, a “Holder”) shall not make any disposition of all or any portion of any Securities unless:

A. there is then in effect a registration statement under the Securities Act, covering such proposed disposition and such disposition is made in accordance with such registration statement; or

B. such Holder has notified the Company of the proposed disposition and has furnished the Company with a statement of the circumstances surrounding the proposed disposition, and, at the expense of such Holder or its transferee, with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require registration of such securities under the Securities Act.

## 7.2 Exceptions to Restrictions

Notwithstanding 7.1, no such registration statement or opinion of counsel will be required: (i) for any transfer of any Securities in compliance with the Securities and Exchange Commission’s Rule 144 or Rule 144A, or (ii) for any transfer of any Securities by a Holder that is a partnership, limited liability company, a corporation, or a venture capital fund to (A) a partner of such partnership, a member of such limited liability company, or Purchaser of such corporation, (B) an affiliate of such partnership, limited liability company or corporation (including, any affiliated investment fund of such Holder), (C) a retired partner of such partnership or a

retired member of such limited liability company, (D) the estate of any such partner, member, or Purchaser, or (iii) for the transfer without additional consideration or at no greater than cost by gift, will, or intestate succession by any Holder to the Holder’s spouse or lineal descendants or ancestors or any trust for any of the foregoing; provided that, in the case of clauses (ii) and (iii), the transferee agrees in writing to be subject to the terms of this Agreement to the same extent as if the transferee were an original Purchaser under this Agreement.

## 7.3 “Market Stand-Off” Agreement

To the extent requested by the Company or an underwriter of securities of the Company, each Holder shall not sell or otherwise transfer or dispose of any Securities or other shares of stock of the Company then owned by such Holder (other than to donees or partners of the Holder who agree to be similarly bound) for up to 180 days following the effective date of any registration statement of the Company filed under the Securities Act; provided however that, if during the last 17 days of the restricted period the Company issues an earnings release or material news or a material event relating to the Company occurs, or before the expiration of the restricted period the Company announces that it will release earnings results during the 16-day period beginning on the last day of the restricted period, and if the Company’s securities are listed on the Nasdaq Stock Market and Rule 2711 thereof applies, then the restrictions imposed by this Section 6.3 will continue to apply until the expiration of the 18-day period beginning on the issuance of the earnings release or the occurrence of the material news or material event; provided, further, that such automatic extension will not apply to the extent that the Financial Industry Regulatory Authority has amended or repealed NASD Rule 2711(f)(4), or has otherwise provided written interpretive guidance regarding such rule, in each case, so as to eliminate the prohibition of any broker, dealer, or member of a national securities association from publishing or distributing any research report, with respect to the securities of an “emerging growth company” (as defined in the Jumpstart Our Business Startups Act of 2012) before or after the expiration of any agreement between the broker, dealer, or member of a national securities association and the emerging growth company or its Purchasers that restricts or prohibits the sale of securities held by the emerging growth company or its Purchasers after the initial public offering date. In no event will the restricted period extend beyond 215 days after the effective date of the registration statement. For purposes of this Section 7.3, “Company” includes any wholly-owned subsidiary of the Company into which the Company merges or consolidates. The Company may place restrictive legends on the certificates representing the shares subject to this Section 7.3 and may impose stop-transfer instructions with respect to the Securities

and such other shares of stock of each Holder (and the shares or securities of every other person subject to the foregoing restriction) until the end of such period. Each Holder shall enter into any agreement reasonably required by the underwriters to implement the foregoing within any reasonable timeframe so requested.

# Section 8: General Provisions

## 8.1 Successors and Assigns
The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties to this Agreement or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. No Purchaser may transfer Shares unless each transferee agrees to be bound by the terms of this Agreement.

## 8.2 Governing Law
This Agreement is governed by the law of Wyoming, regardless of the laws that might otherwise govern under applicable principles of choice of law.

## 8.3 Counterparts; Facsimile or Electronic Signature
This Agreement may be executed and delivered by facsimile or electronic signature and in two or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.

## 8.4 Titles and Subtitles
The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.

## 8.5 Notices
All notices and other communications given or made pursuant to this Agreement must be in writing and will be deemed to have been given upon the earlier of actual receipt or: (a) personal delivery to the party to be notified, (b) when sent, if sent by facsimile or electronic mail during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient's next business day, (c) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one business day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt. All communications must be sent to the respective parties at their address as recorded by Wefunder Portal, LLC and/or as set forth on the signature page, or to such address, facsimile number or electronic mail address as subsequently modified by written notice given in accordance with this Section 10.5.

## 8.6 No Finder's Fees
Each party severally represents to the other parties that it neither is nor will be obligated for any finder's fee or commission in connection with this transaction. Each Purchaser shall indemnify, defend, and hold harmless the Company from any liability for any commission or compensation in the nature of a finder's or broker's fee arising out of this transaction (and the costs and expenses of defending against such liability or asserted liability) for which the Purchaser or any of its officers, employees, or representatives is responsible. The Company shall indemnify, defend, and hold harmless each Purchaser from any liability for any commission or compensation in the nature of a finder's or broker's fee arising out of this transaction (and the costs and expenses of defending against such

liability or asserted liability) for which the Company or any of its officers, employees or representatives is responsible.

## 8.7 Attorneys' Fees
If any action at law or in equity (including arbitration) is necessary to enforce or interpret the terms of this Agreement, the prevailing party will be entitled to reasonable attorneys' fees, costs, and necessary disbursements in addition to any other relief to which the party may be entitled. Each party shall pay all costs and expenses that it incurs concerning the negotiation, execution, delivery, and performance of the Agreement.

## 8.8 Amendments and Waivers
Except as set forth in Section 3.1(B) and as otherwise specified in this Agreement, any term of this Agreement may be amended, terminated or waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Company and the Purchasers holding a majority of the then-outstanding shares of Series Seed Preferred Stock (or Common Stock issued on conversion thereof). Notwithstanding the foregoing, the addition of a party to this Agreement pursuant to a transfer of Preferred Shares in accordance with applicable provisions of this Agreement will not require any further consent. Any amendment or waiver effected in accordance with this Section will be binding upon the Purchasers, the Founders, each transferee of the shares of Series Seed Preferred Stock (or the Common Stock issuable upon conversion thereof) or Common Stock, as applicable, and each future holder of all such securities, and the Company. It is specifically intended that entering into the Next Financing Agreements shall be considered an amendment to this Agreement provided that it is done in accordance with this Section 10.8.

## 8.9 Severability
The invalidity or unenforceability of any provision of this Agreement will in no way affect the validity or enforceability of any other provision.

## 8.10 Delays or Omissions
No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, will impair any such right, power or remedy of such non-breaching or non-defaulting party nor will it be construed to be a waiver of any such breach or default or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor will any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party, are cumulative and not alternative.

## 8.11 Termination
Unless terminated earlier pursuant to the terms of this Agreement, (i) the rights, duties, and obligations under Sections 5 and 9 will terminate immediately prior to the closing of the Company's initial public offering of Common Stock pursuant to an effective registration statement filed under the Securities Act, (ii) notwithstanding anything to the contrary herein, this Agreement (excluding any then-existing obligations) will terminate upon the closing of a Deemed Liquidation Event as defined in the Company's Restated Articles, as amended from time to time and (3) notwithstanding anything to the contrary herein, Section 2, Section 4, Section 6, Section 5.2 and this Section 8 will survive any termination of this Agreement.

8.12 Dispute Resolution. Each party (a) hereby irrevocably and unconditionally submits to the personal jurisdiction of the state of Nevada for the purpose of any suit,

action, or other proceeding arising out of or based upon this Agreement; (b) shall not commence any suit, action or other proceeding arising out of or based upon this Agreement except in Nevada; and (c) hereby waives, and shall not assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject to the personal jurisdiction of Nevada, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement, or the subject matter hereof and thereof may not be enforced in or by Nevada.

8.13 Entire Agreement. This Agreement together with the Restated Articles constitute the full and entire understanding and agreement between the parties concerning the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the parties have executed this agreement as of [EFFECTIVE DATE]

Number of Shares: [SHARES]

Aggregate Purchase Price: $[AMOUNT]

## COMPANY:
OsNovum

## Founder Signature

Name: [FOUNDER_NAME]
Title: [FOUNDER_TITLE]

## Read and Approved (For IRA Use Only):
By:

## SUBSCRIBER:
[ENTITY NAME]

## Investor Signature

By:
Name: [INVESTOR NAME]
Title: [INVESTOR TITLE]

The Subscriber is an “accredited investor” as that term is defined in Regulation D promulgated by the Securities and Exchange Commission under the Securities Act.

Please indicate Yes or No by checking the appropriate box:

☐ Accredited
☑ Not Accredited

SIGNATURE PAGE
TO
SUBSCRIPTION AGREEMENT

**Attachment 4:** `document_4.pdf`

Osnovum I (THE "SPV"), a series of Wefunder SPV, LLC, a Delaware limited liability company (the "LLC")

# Subscription Agreement

## $[INVESTMENT AMOUNT]

[INVESTMENT DATE]

Osnovum I (the "SPV"), a series of Wefunder SPV, LLC (the "LLC"), is a special purpose vehicle that will invest all of its assets in securities issued by OsNovum (the "Company"). By making an investment in the SPV through the Wefunder website, I understand and agree to the representations set forth below.

I have reviewed the following information and documents in connection with this Subscription Agreement:

1. The information on the Wefunder website about the Company. I acknowledge that this information was prepared solely by either the Company or a third party whose work has been verified by the Company, and that none of Wefunder, Inc., Wefunder Portal, LLC, Wefunder Admin, LLC or Wefunder Advisors, LLC, nor any of their affiliates, employees or agents, are responsible for the adequacy, completeness, or accuracy of this information;

2. The Form C relating to this investment, which provides information about investment in the Company through the use of the SPV;

3. The Series Appendix, an appendix to the Wefunder SPV, LLC limited liability company agreement (the "LLC Agreement"), which sets forth certain specific terms of the SPV;

4. The Terms Appendix, which summarizes the terms of the Company securities to be purchased by the SPV;

5. The LLC Agreement, which sets forth other terms applicable to each SPV;

6. This Subscription Agreement, which sets forth the terms governing your investment in the SPV, and that sets forth certain representations you are making in connection with your investment in the SPV;

7. The Wefunder Investor Agreement; and

8. The Wefunder Terms of Service.

By making an investment in the SPV through the Wefunder website, I agree to be bound by this Subscription Agreement and the terms of the other agreements listed above with respect to my investment in the SPV.

# Subscription Agreement

## SCOPE OF AGREEMENT AND INVESTOR ELIGIBILITY REPRESENTATIONS

A. This agreement ("Agreement") applies to each investment in a series ("SPV") of Wefunder SPV, LLC (the "LLC"). Each series is a separate pool of assets from every other series. Each SPV will invest all of its assets in securities issued by a single company ("Company") as set forth in the applicable series appendix ("Series Appendix") to the Wefunder SPV, LLC limited liability company agreement ("LLC Agreement"). The terms of the Company securities to be purchased by the SPV are summarized in an appendix ("Terms Appendix") attached to this Agreement.

B. Each SPV is formed by and operated by Wefunder Admin, LLC on behalf of the Company in whose securities that SPV invests.

C. Important information about the Company, about the related SPV, and more generally about investments through the Wefunder website, is available through the Wefunder website. The Investor should review that information, and all relevant Company Information (as defined below), carefully before making an investment in any SPV.

D. Each SPV will offer membership interests ("Interests") in that SPV pursuant to Regulation Crowdfunding under the U.S. Securities Act of 1933, as amended (the "Securities Act").

E. You hereby agree that each time you make an investment in any SPV, you will be deemed to have entered into this Agreement, and will be deemed to have made each representation and covenant contained in this Agreement.

F. Except as the context otherwise requires, any reference in this Subscription Agreement to:

1. a "SPV" shall mean "The LLC acting solely on behalf of and for the account of the SPV";

2. "Investor" and "you" shall mean a person (whether individually, jointly with another person, or through his or her individual retirement account) who has agreed to invest, or has invested, in any SPV; and

3. "Company Information" means:

a. The information on the Wefunder website about the Company. I acknowledge that this information was prepared solely by either the Company or a third party whose work has been verified by the Company, and that neither Wefunder, Inc., Wefunder Portal, LLC, Wefunder Admin, LLC or Wefunder Advisors, LLC (together, the "Wefunder entities," nor any of their affiliates, employees or agents, are responsible for the adequacy, completeness, or accuracy of this information;

b. The Form C relating to this investment, which provides information about investment in the Company through the use of the SPV;

c. The Series Appendix, an appendix to the Wefunder SPV, LLC limited liability company agreement (the "LLC Agreement"), which sets forth certain specific terms of the SPV;

d. The Terms Appendix, which summarizes the terms of the Company securities to be purchased by the SPV;

e. The LLC Agreement, which sets forth other terms applicable to each SPV;

f. This Subscription Agreement, which sets forth the terms governing your investment in the SPV, and that sets forth certain representations you are making in connection with your investment in the SPV;

g. The Wefunder Investor Agreement; and

h. The Wefunder Terms of Service.

INVESTOR'S REPRESENTATIONS AND COVENANTS

## 1. Investor's Review of Information and Investment Decision

1.1. The Investor has carefully read and understands the Company Information. The Investor acknowledges that it has made an independent decision to invest indirectly in the Company through the SPV and that, in making its decision to invest in a SPV, the Investor has relied solely upon the Company Information, any other relevant information on the Wefunder website, and independent investigations made by the Investor. The Investor understands that no representations or warranties have been made to the Investor by the LLC, the relevant SPV, any administrator appointed from time to time with respect to the SPV (the "Administrator"), any lead investor appointed from time to time with respect to the SPV (the "Lead Investor"), or any partner, member, officer, employee, agent, affiliate or subsidiary of any of them regarding the Company.

1.2. The Investor has been provided an opportunity to request additional information concerning the Company and the offering through the Ask A Question feature on wefunder.com.

1.3. The Investor understands and agrees that neither Wefunder, Inc., Wefunder Portal, LLC, Wefunder Admin, LLC, any of their affiliates, nor any director, manager, officer, shareholder, member, employee or agent of Wefunder, Inc., Wefunder Portal, LLC, Wefunder Admin, LLC or any of their affiliates (each, a "Wefunder Party," and collectively, "Wefunder Parties") shall be liable in connection with any information or omission of information contained in materials prepared or supplied by the Company. Such materials may include, but are not limited to, information provided by the Company in the Form C related to the offering, information available through the Wefunder website, and materials distributed to the Investor by the SPV on behalf of a Company.

1.4. The Investor represents and agrees that no Wefunder Party has recommended or suggested any investment in a SPV, or any investment related to a Company, to the Investor.

1.5. Investor understands that no Wefunder Party is an adviser to Investor, and that Investor is not an advisory or other client of any Wefunder Party.

1.6. The Investor is not relying on any Wefunder Party or any other person or entity with respect to the legal, accounting, business, investment, pension, tax or other economic considerations involved in this investment other than the Investor's own advisers that are not affiliated with any of the foregoing persons.

1.7. The Investor has such knowledge and experience in financial and business matters that the Investor is capable of evaluating the merits and risks of the Investor's investment in the SPV and is able to bear such risks. The Investor has obtained, in the Investor's judgment, sufficient information to evaluate the merits and risks of such investment. The Investor has evaluated the risks of investing in the SPV, understands there are substantial risks of loss incidental to the purchase of an Interest and has determined that the Interest is a suitable investment for the Investor and consistent with the general investment objectives of the Investor.

## 2. Investor's Representations Related To Investment in a SPV

2.1. The Investor is acquiring the Interest for its own account, for investment purposes only and not with an intent to resell or distribute the Interest (or any distributions received from the SPV in whole or in part), and the Investor agrees that it will not sell or otherwise transfer the Interest unless in compliance with Regulation Crowdfunding and other applicable securities laws, and with the terms and conditions of this Agreement.

2.2. The Investor's investment in the Interest is consistent with the investment purposes, objectives and cash flow requirements of the Investor and will not adversely affect the Investor's overall need for diversification and liquidity.

2.3. The Investor has all requisite power, authority and capacity to acquire and hold the Interest and to execute, deliver and comply with the terms of each of the instruments required to be executed and delivered by the Investor in connection with the Investor's subscription for the Interest, including without limitation this Subscription Agreement, and such execution, delivery and compliance does not conflict with, or constitute a default under, any instruments governing the Investor, any law, regulation or order, or any agreement or other undertaking to which the Investor is a party or by which the Investor may be bound. If the Investor is an entity, the person executing and delivering each of such instruments on behalf of the Investor has all requisite power, authority and capacity to execute and deliver such instruments, and, upon request by the SPV, will furnish to the SPV a true and correct copy of any instruments governing the Investor, including all amendments thereto. The signature on each of such instruments is genuine and each of such instruments constitutes a legal, valid and binding obligation of the Investor enforceable against the Investor in accordance with its terms.

2.4. The Wefunder Parties are each hereby authorized and instructed to accept and execute any instructions in respect of the Interest given by the Investor in written or electronic form. The Wefunder Parties may rely conclusively upon and shall incur no liability in respect of any action take upon any notice, consent, request, instructions or other instrument believed in good faith to be genuine or to be signed by properly authorized persons of the Investor.

2.5. Pursuant to the requirements of Treas. Reg. § 301.6109-1(c), the Investor has provided, or agrees to provide upon the earlier of (i) two years of an acquisition of an Interest or (ii) twenty (20) days before any distribution is to be made from the SPV, his, her or its taxpayer identification number (e.g., social security number or employer identification number) under penalties of perjury and has or will attest that the Internal Revenue Service has not notified the Investor that he, she or it is subject to backup withholding.

3. The Manager Has The Right To Reject Any Subscription, In Whole Or In Part.

3.1. The Investor understands that the SPV will not register as an investment company under the U.S. Investment Company Act of 1940, as amended (the "Investment Company Act"), nor will it make a public offering of its securities within the United States.

3.2. The Investor understands that the value of all investments in any SPV made through individual retirement accounts ("IRAs") must be less than 25% of the value of the SPV's assets.

3.3. If the Investor is investing in a SPV through an employee benefit plan of any kind, including an individual retirement account (the "Plan"), and an individual or entity (the "Fiduciary") has entered into this Agreement on behalf of the Plan, the Fiduciary hereby makes the following representations, warranties, and covenants:

i. The Fiduciary is a fiduciary of the Plan who is authorized to invest Plan assets or is acting at the direction of a Plan fiduciary authorized to invest Plan assets. The Fiduciary has determined that an investment in the Fund is consistent with the Fiduciary's responsibilities to the Plan under Employee Retirement Income Security Act of 1974, as amended ("ERISA") or other applicable law, and is qualified to make such investment decision. The Fiduciary is authorized to make all representations, covenants and agreements set forth in this Agreement about and on behalf of the Investor, and the Fiduciary hereby agrees that, except for the representations, covenants and agreements contained in this section 3.3. all representations, covenants and agreements contained in this Agreement are made on behalf of the Investor who is investing through the Plan.

ii. The execution and delivery of this Subscription Agreement, and the investment contemplated hereby has been duly authorized by all appropriate and necessary parties pursuant to the provisions of the instrument or instruments governing the Plan and any related trust; and (B) will not violate, and is not otherwise inconsistent with, the terms of such instrument or instruments.

iii. The Fiduciary acknowledges that the assets of the Fund will be invested in accordance with the Company Information related to that Fund.

iv. The Plan's purchase and holding of an Interest will not constitute a non-exempt transaction prohibited under ERISA, Section 4975 of the Internal Revenue Code (the "Code"), or any similar laws or other federal, state, local, foreign or other laws or regulations applicable to the Plan and its investments. None of the Wefunder entities nor any of their affiliates, agents, or employees: (A) exercises any authority or control with respect to the management or disposition of assets of the Plan used to purchase an Interest, (B) renders investment advice for a fee (pursuant to an agreement or understanding that such advice will serve as a primary basis for investment decisions and that such advice will be based on the particular investment needs of the Plan), with respect to such assets of the Plan, or has the authority to do so, or (C) is an employer maintaining or contributing to, or any of whose employees are covered by, the Plan.

v. The Fiduciary understands and agrees to the fee arrangements described in the Company Information.

vi. The Fiduciary understands and agrees that, to prevent the assets of the SPV from being treated as "plan assets" for purposes of ERISA and Section 4975 of the Code, the Investor may be prohibited from purchasing or acquiring an Interest or may be required to redeem its Interest or a portion thereof.

3.4. The Investor acknowledges that the SPV and any Administrator, on the SPV's behalf, may not accept any investment from an Investor if the Investor cannot truthfully make the representations contained herein.

4. The Correctness And Accuracy Of All Information Provided By Investor To The LLC Or The SPV.

4.1. The Investor confirms that all information and documentation provided to the LLC, the SPV, and any Administrator, including, but not limited to, all information regarding the Investor's identity, taxpayer identification number, the source of the funds to be invested in the SPV, and the Investor's eligibility to invest in offerings under Regulation Crowdfunding, is true, correct and complete. Should any such information change or no longer be accurate, the Investor agrees and covenants that they will promptly notify the Wefunder Parties of such changes via the wefunder.com platform. The Investor agrees and covenants that he, she or it will maintain accurate and up-to-date contact information (including email and mailing address) on the wefunder.com platform and will promptly update such information in the event it changes or is no longer accurate.

4.2. The representations, warranties, agreements, undertakings and acknowledgments made by the Investor in this Subscription Agreement will be relied upon by the LLC, the SPV, and any Administrator in determining the Fund's compliance with federal and state securities laws, and shall survive the Investor's admission as a Member of the SPV.

4.3. All information that the Investor has provided to the LLC, the SPV, and any Administrator concerning the knowledge and experience of financial, tax and business matters of the Investor is correct and complete.

5. The Wefunder Parties' Right To Use Investor Information.

5.1. The Investor agrees and consents to the Wefunder Parties, their delegates and their duly authorized agents and any of their respective related, associated or affiliated companies obtaining, holding, using, disclosing and processing the Investor's data:

a. to facilitate the acceptance, management and administration of the Investor's subscription for an Interest on an on-going basis;

b. for any other specific purposes where the Investor has given specific consent to do so;

c. to carry out statistical analysis, market research, and tracking of investment performance over time;

d. to comply with legal or regulatory requirements applicable to the SPV and any Administrator or the Investor, including, but not limited to, in connection with anti-money laundering and similar laws;

e. for disclosure or transfer to third parties including the Investor's financial adviser (where appropriate), regulatory bodies, auditors, technology providers or to the SPV, any Administrator, any Lead Investor, and their delegates or their duly appointed agents and any of their respective related, associated or affiliated companies for the purposes specified above;

f. if the contents thereof are relevant to any issue in any action, suit or proceeding to which the LLC, the SPV, any Administrator, any Lead Investor, or their affiliates are a party or by which they are or may be bound;

g. for other legitimate business of the LLC, the SPV, any Administrator, or any Lead Investor.

5.2. The Investor acknowledges and agrees that it will provide additional information or take such other actions as may be necessary or advisable for the SPV or any Administrator (in the sole judgment of the SPV and/or any Administrator) to comply with any disclosure and compliance policies, related legal process or appropriate requests (whether formal or informal) or otherwise.

5.3. The Investor agrees and consents to disclosure by the LLC, the SPV and any of their agents, including any Administrator or any Lead Investor, to relevant third parties of information pertaining to the Investor in respect of disclosure and compliance policies or information requests related thereto. Without limiting the generality of the foregoing, the Investor agrees that information about the Investor may be provided to the Company in whose securities a SPV will or proposes to invest.

5.4. The Investor authorizes the LLC, the SPV, any Administrator, and each SPV service provider to disclose the Investor's nonpublic personal information to comply with regulatory and contractual requirements applicable to the SPV and its investments. Any such disclosure shall be permitted notwithstanding any privacy policy or similar restrictions regarding the disclosure of the Investor's nonpublic personal information.

6. Key Risk Factors

6.1. The Investor understands that investment in a SPV may involve a complete loss of the Investor's investment. In this regard, the Investor understands that such venture investments involve a high degree of risk, and that many or most venture company investments lose money. An Investor may ultimately receive cash, securities, or a combination of cash and securities (and in many cases nothing at all). If the Investor receives securities, the securities may not be publicly traded, and may not have any significant value.

6.2. The Investor understands and agrees that the Interests are subject to restrictions on transfer and cannot be redeemed. Instead, an Investor typically must hold his or her Interest in a SPV until the SPV has sold or otherwise disposed of its investments and the SPV distributes its investments to the investors in the SPV (a "Liquidation Event"). An Investor typically will not receive any distributions until such a Liquidation Event (and may not receive anything even upon a Liquidation Event), which may not occur for many years. The Investor must therefore bear the economic risk of holding their investment for an indefinite period of time.

6.3. The Investor understands and agrees that the Interests: (a) have not been registered under the Securities Act or any other law of the United States, or under the securities laws of any state or other jurisdiction, and therefore an Interest cannot be resold, pledged, assigned or otherwise disposed of unless it is so registered or an exemption from registration is available; and (b) can only be transferred as permitted under Regulation Crowdfunding and subject to the terms and conditions of this Agreement.

6.4. The Investor understands that no guarantees have been made to the Investor about future performance or financial results of the SPV, and an investment in the SPV may result in a gain or loss upon termination or liquidation of the SPV. It is possible that the investors in a SPV will have "phantom income," which could require them to pay taxes on their investment in a SPV even though the SPV does not distribute any income (or does not distribute sufficient income to pay the taxes).

6.5. The Investor understands and agrees that the SPV was formed by and is operated by Wefunder Admin, LLC on behalf of the Company. Investors will have no right to manage or influence the management of any SPV or of the LLC.

6.6. The Investor understands the Issuer may be required to pay an administrative fee for maintenance and operation of the SPV. Failure of the Issuer to pay such a fee could result in the dissolution of the SPV (an "SPV Dissolution Event"). Subsequent to an SPV Dissolution Event, the securities held by the SPV would be distributed directly and proportionally to the individual investors. The Investor understands that dissolution of the SPV pursuant to an SPV Dissolution Event could create administrative complexities, as investors would need to manage the securities themselves rather than having them held and administered by the SPV. Additionally, the unplanned distribution of securities may not align with investors' intended investment strategy or asset allocation. Upon an SPV Dissolution Event, the Investor hereby consents to and agrees to accept direct assignment of the SPV's rights and obligations under any investment agreements between the SPV and the Issuer that is located in the Form C or C/A offering materials. The Investor acknowledges they will be bound by all terms and conditions of such agreements as if they were an original party thereto.

6.7. The Investor understands and agrees that the Company may appoint a Lead Investor and that, if appointed, pursuant to a power of attorney granted by the Investor in the Investor Agreement, the Lead Investor will exercise voting authority on behalf of the Investor with respect to the SPV securities the Investor owns.

6.8. The Investor represents that he or she has read and understands the risk factors contained in the Company Information. The Investor understands and agrees that each Company is solely responsible for providing risk factors, conflicts of interest, and other disclosures that investors should consider when investing in securities issued by that Company (including through a SPV), and that the Wefunder Parties have no ability to assure, and have not in any way assured, that any or all such risk factors, conflicts of interest and other disclosures have been presented fully and fairly, or have been presented at all.

6.9. The Investor understands that any privacy statements, reports or other communications regarding the SPV and the Investor's investment in the SPV (including annual and other updates, and tax documents) will be delivered via electronic means, including through wefunder.com. The Investor hereby consents to electronic delivery as described in the preceding sentence. In so consenting, the Investor acknowledges that email messages are not secure and may contain computer viruses or other defects, may not be accurately replicated on other systems, or may be intercepted, deleted or interfered with, with or without the knowledge of the sender or the intended recipient. The Investor also acknowledges that an email from the Wefunder Parties may be accessed by recipients other than the Investor and may be interfered with, may contain computer viruses or other defects and may not be successfully replicated on other systems. No Wefunder Party gives any warranties in relation to these matters.

6.10. The Investor understands and agrees that if he, she or it does not provide a valid taxpayer identification number under penalties of perjury, and attest that the Investor has not been notified by the Internal Revenue Service that he, she or it is subject to backup withholding, the SPV will be required to withhold from any proceeds otherwise payable to the Investor an amount necessary to satisfy the SPV's backup withholding obligations.

6.11. The Investor understands and agrees that if he, she or it does not provide a valid taxpayer identification number to the SPV, the SPV will withhold from any proceeds otherwise payable to the Investor an amount necessary for the SPV to satisfy its tax withholding obligations with respect to such amount. The SPV may also withhold any other amounts representing the SPV's reasonable estimation of penalties that may be charged by the Internal Revenue Service or any other taxing authority as a result of the Investor's failure to provide a valid taxpayer identification number.

6.12. The Investor understands that the Issuer may be required to pay to Wefunder certain fees for the rendering of tax services and may be required to furnish Wefunder with certain tax documents in connection with these services. These obligations are specified in the Tax Services Agreement ("TSA"), where applicable. The Investor further understands and agrees that failure by the Issuer to pay such fees or failure to deliver required tax documents in the manner prescribed in the TSA, may each constitute an SPV Dissolution Event, the consequences of which are detailed in Section 6.6.

## 7. Compliance With Anti-Money Laundering Laws.

7.1. The Investor represents and warrants that the Investor's investment was not directly or indirectly derived from illegal activities, including any activities that would violate U.S. Federal or State laws or any laws and regulations of other countries.

7.2. The Investor acknowledges that U.S. Federal law, regulations and Executive Orders administered by the U.S. Treasury Department's Office of Foreign Assets Control ("OFAC") may prohibit the SPV, any Administrator, or any Lead Investor from, among other things, engaging in transactions with, and the provision of services to, persons on the list of Specially Designated Nationals and Blocked Persons and persons, foreign countries and territories that are the subject of U.S. sanctions administered by OFAC (collectively, the "OFAC Maintained Sanctions").

7.3. The Investor acknowledges that the SPV prohibits the investment of funds by any persons or entities that are (i) the subject of OFAC Maintained Sanctions, (ii) acting, directly or indirectly, in contravention of any applicable laws and regulations, including anti-money laundering regulations or conventions, or on behalf of persons or entities subject to an OFAC Maintained Sanction, (iii) acting, directly or indirectly, for a senior foreign political figure, any member of a senior foreign political figure's immediate family or any close associate of a senior foreign political figure, unless the SPV, after being specifically notified by the Investor in writing that it is such a person, conducts further due diligence, and determines that such investment shall be permitted, or (iv) acting, directly or indirectly, for a foreign shell bank (such persons or entities in (i) - (iv) are collectively referred to as "Prohibited Persons"). The Investor represents and warrants that it is not, and is not acting directly or indirectly on behalf of, a Prohibited Person.

7.4. To the extent the Investor has any beneficial owners, (i) it has carried out thorough due diligence to

establish the identities of such beneficial owners, (ii) based on such due diligence, the Investor reasonably believes that no such beneficial owners are Prohibited Persons, (iii) it holds the evidence of such identities and status and will maintain all such evidence for at least five years from the date of the liquidation or termination of the SPV, and (iv) it will make available such information and any additional information requested by the SPV that is required under applicable regulations.

7.5. The Investor acknowledges and agrees that the SPV or any Administrator may "freeze the account" of the Investor, including, but not limited to, by suspending distributions from the SPV to which the Investor would otherwise be entitled, if necessary to comply with anti-money laundering statutes or regulations.

7.6. The Investor acknowledges and agrees that the SPV and/or any Administrator, in complying with anti-money laundering statutes, regulations and goals, may file voluntarily and/or as required by law suspicious activity reports ("SARs") or any other information with governmental and law enforcement agencies that identify transactions and activities that the SPV or any Administrator or their agents reasonably determine to be suspicious, or is otherwise required by law. The Investor acknowledges that the LLC, the SPV, and any Administrator are prohibited by law from disclosing to third parties, including the Investor, any filing or the substance of any SARs.

7.7. The Investor agrees that, upon the request of the LLC, the SPV, or any Administrator, it will provide such information as the LLC, the SPV, or any Administrator requires to satisfy applicable anti-money laundering laws and regulations, including, without limitation, background documentation about the Investor

## 8. Regulatory Provisions

8.1. The Investor understands that no federal or state agency has passed upon the Interests or made any findings or determination as to the fairness of this investment.

8.2. The Investor certifies that the information contained in the executed copy of Form W-9 submitted to the SPV (if any) and/or the taxpayer identification provided to the SPV is correct. The Investor agrees to provide such other documentation as the SPV determines may be necessary for the SPV to fulfill any tax reporting and/or withholding requirements.

8.3. The Investor understands and agrees that the Company may cause the SPV to make an election under Section 754 of the Internal Revenue Code (the "Code") or an election to be treated as an "electing investment partnership" for purposes of Section 743 of the Code. If the SPV elects to be treated as an electing investment partnership, the Investor shall cooperate with the SPV to maintain that status and shall not take any action that would be inconsistent with such election. Upon request, the Investor shall provide the SPV with any information necessary to allow the SPV to comply with (a) its obligations to make tax basis adjustments under Section 734 or 743 of the Code and (b) its obligations as an electing investment partnership.

8.4. The Investor consents to receive any Schedule K-1 (Partner's Share of Income, Deductions, Credits, etc.) from the SPV electronically via email, the Internet and/or another electronic reporting medium in lieu of paper copies. The Investor agrees that it will confirm this consent electronically at a future date in a manner set forth by the Company at such time and as required by the electronic receipt consent rules set forth by the Internal Revenue Service. The Investor may request a paper copy of the Investor's Schedule K-1 by contacting Wefunder Inc. at support@wefunder.com or such other email address as specified on the wefunder.com platform. Requesting a paper copy will not constitute a withdrawal of the Investor's consent to receive reports or other communications, including Schedule K-1, electronically. The Investor may withdraw its consent for electronic delivery or change its contact preferences for such delivery at any time by writing to support@wefunder.com or such other email address as specified on the wefunder.com platform. Such withdrawal will take effect promptly after receipt, unless otherwise agreed upon. Upon receipt of a withdrawal request, the SPV will confirm the withdrawal and the date on which it takes effect in writing (either electronically or on paper). A withdrawal of consent does not apply to a statement that was furnished electronically before the date on which the withdrawal of consent takes effect. The SPV will cease providing information electronically upon termination of the SPV. Notwithstanding the Investor's consent to receive materials electronically, the Investor still may be required to print and attach its Schedule K-1 to a federal, state or local tax return.

## 9. Miscellaneous Provisions

### 9.1. Indemnification

9.1.1. The Investor agrees to indemnify and hold harmless the LLC, the SPV, any Administrator, any Lead Investor, or any partner, member, officer, employee, agent, affiliate or subsidiary of any of them, and each other person, if any, who controls, is controlled by, or is under common control with, any of the foregoing, within the meaning of Section 15 of the Securities Act, and their respective officers, directors, partners, members, shareholders, owners, employees and agents (collectively, the "Indemnified Parties") against any and all loss, liability, claim, damage and expense whatsoever (including all expenses reasonably incurred in investigating, preparing or defending against any claim whatsoever) arising out of or based upon (i) any false representation or warranty made by the Investor, or breach or failure by the Investor to comply with any covenant or agreement made by the Investor, in this Subscription Agreement or in any other document furnished by the Investor to any of the foregoing in connection with this transaction, or (ii) any action for securities law violations instituted by the Investor that is finally resolved by judgment against the Investor.

9.1.2. The Investor also agrees to indemnify each Indemnified Party for any and all costs, fees and expenses (including legal fees and disbursements) in connection with any damages

resulting from the Investor's misrepresentation or misstatement contained herein, or the assertion of the Investor's lack of proper authorization from the beneficial owner to enter into this Subscription Agreement or perform the obligations hereof.

9.1.3. The Investor agrees to indemnify and hold harmless each Indemnified Party from and against any tax, interest, additions to tax, penalties, reasonable attorneys' and accountants' fees and disbursements, together with interest on the foregoing amounts at a rate determined by the SPV or any Administrator computed from the date of payment through the date of reimbursement, arising from the failure to withhold and pay over to the U.S. Internal Revenue Service or the taxing authority of any other jurisdiction any amounts computed, as required by applicable law, with respect to the income or gains allocated to or amounts distributed to the Investor with respect to its Interest during the period from the Investor's acquisition of the Interest until the Investor's transfer of the Interest in accordance with this Agreement, the LLC Agreement, and Regulation Crowdfunding.

9.1.4. If for any reason (other than the willful misfeasance or gross negligence of the entity that would otherwise be indemnified) the foregoing indemnification is unavailable to, or is insufficient to hold such Indemnified Party harmless, then the Investor shall contribute to the amount paid or payable by the Indemnified Party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect not only the relative benefits received by the Investor on the one hand and the Indemnified Parties on the other but also the relative fault of the Investor and the Indemnified Parties, as well as any relevant equitable considerations.

9.1.5. The reimbursement, indemnity and contribution obligations of the Investor under this section shall be in addition to any liability that the Investor may otherwise have, and shall be binding upon and inure to the benefit of any successors, assigns, heirs and personal representatives of the Indemnified Parties.

9.2. **Limitation of Liability.** The LLC is a Delaware "multi-series" limited liability company. As a multi-series limited liability company, the LLC may operate multiple series with the benefit of segregation of assets and liabilities among each of its series pursuant to the Delaware Limited Liability Company Act, as amended (the "Delaware Act"). Accordingly, the Investor hereby agrees that the debts, liabilities, obligations and expenses incurred, contracted for or otherwise existing with respect to a series (including the SPV) shall be enforceable against the assets of that series only and not against the LLC generally or the assets of any other series. In addition, none of the debts, liabilities, obligations and expenses incurred, contracted for or otherwise existing with respect to the LLC generally, or any particular series, shall be enforceable against the assets of any other series.

9.3. **Counsel.** The Investor understands that Morrison &amp; Foerster LLP serves as legal counsel on certain matters to Wefunder, Inc., Wefunder Portal, LLC, Wefunder Admin, LLC and Wefunder Advisors, LLC and not to the SPV or any Investor by virtue of its investment in the SPV, and that no independent counsel has been retained to represent the SPV or Investors in the SPV. The Investor also understands that Morrison &amp; Foerster LLP has not independently verified any factual assertions made in the Company Information or on the Wefunder website and is not responsible for the SPV's compliance with its investment program or applicable law.

9.4. **Power of Attorney.** The Investor hereby appoints each of the Company and Wefunder Admin, LLC as its true and lawful representative and attorney-in-fact, in its name, place and stead to make, execute, sign, acknowledge, swear to and file:

9.4.1. a Certificate of Formation of the LLC and any amendments required under the Delaware Act

9.4.2. the LLC Agreement and any duly adopted amendments;

9.4.3. any and all instruments, certificates and other documents that may be deemed necessary or desirable to effect the winding-up and termination of the LLC or the SPV (including a Certificate of Cancellation of the Certificate of Formation); and

9.4.4. any business certificate, fictitious name certificate, related amendment or other instrument or document of any kind necessary or desirable to accomplish the LLC's or the SPV's business, purpose and objectives or required by any applicable U.S., state, local or other law.

This power of attorney is coupled with an interest, is irrevocable, and shall survive and shall not be affected by the subsequent death, disability, incompetence, termination, bankruptcy, insolvency or dissolution of the Investor; provided, however, that this power of attorney will terminate upon the substitution of another SPV member for all of the Investor's investment in the LLC or the SPV or upon the liquidation or termination of the LLC or the SPV. The Investor hereby waives any and all defenses that may be available to contest, negate or disaffirm the actions of the LLC, the SPV, and any Administrator taken in good faith under this power of attorney.

9.5. **Confidentiality.**

9.5.1. The Investor agrees that the Company Information and all financial statements (if any), tax reports (if any), portfolio valuations (if any), private placement memoranda (if any), reviews or analyses of potential or actual investments (if any), reports or other materials prepared or produced by the SPV and/or any Administrator and all other documents and information concerning the affairs of the SPV and/or the Fund's investments, including, without limitation, information about the Company, and/or the persons directly or indirectly investing in the SPV (collectively, the "Confidential Information") that the Investor may receive pursuant to or in accordance with the use of the Wefunder website,

an investment in one or more SPVs, or otherwise as a result of its ownership of an Interest in the SPV, constitute proprietary and confidential information about the SPV, any Administrator, and/or any Lead Investor (the "Affected Parties").

9.5.2. The Investor acknowledges that the Affected Parties derive independent economic value from the Confidential Information not being generally known and that the Confidential Information is the subject of reasonable efforts to maintain its secrecy. The Investor further acknowledges that the Confidential Information is a trade secret, the disclosure of which is likely to cause substantial and irreparable competitive harm to the Affected Companies or their respective businesses. The Investor shall not reproduce any of the Confidential Information or portion thereof or make the contents thereof available to any third party other than a disclosure on a need-to-know basis to the Investor's legal, accounting or investment advisers, auditors and representatives (collectively, "Advisers"), except to the extent compelled to do so in accordance with applicable law (in which case the Investor shall promptly notify the SPV of the Investor's obligation to disclose any Confidential Information) or with respect to Confidential Information that otherwise becomes publicly available other than through breach of this provision by the Investor.

9.5.3. To the fullest extent permitted by law, the Investor agrees not to request disclosure or inspection of any such information after the Investor is notified (whether in response to the Investor's request for information or otherwise) that the SPV has determined not to disclose such information.

9.5.4. The Investor agrees that the LLC, the SPV, and the SPV service providers would be subject to potentially irreparable injury as a result of any breach by the Investor of the covenants and agreements set forth in this Item 9.5, and that monetary damages would not be sufficient to compensate or make whole the LLC, the SPV, and the SPV services providers for any such breach. Accordingly the Investor agrees that the LLC, the SPV, and the SPV service providers shall be entitled to equitable and injunctive relief, on an emergency, temporary, preliminary and/or permanent basis, to prevent any such breach or the continuation thereof.

9.6. Amendments. Neither this Subscription Agreement nor any term hereof may be supplemented, changed, waived, discharged or terminated except with the written consent of the Investor and the Company on behalf of the relevant SPV. For the sake of clarity, the restriction on the Company in the preceding sentence applies solely to the form of this Subscription Agreement applicable to SPVs that have had a closing, and does not prevent the Company from changing the form and content of this Subscription Agreement for use in offerings of SPVs that have not had a closing.

9.7. Assignability and Transferability. This Subscription Agreement is not transferable or assignable by the Investor without the prior written consent of the Company on behalf of the SPV, and any transfer or assignment in violation of this provision shall be null and void. The Interests in the SPV being acquired by Investor herein may only be transferred by Investor in compliance with Regulation Crowdfunding and the terms and conditions of this Agreement. If Investor seeks to transfer the Interests, Investor shall first give written notice to the Company and Wefunder Admin, LLC, including the number of Interests that Investor desires to transfer, the proposed price, the name and contact information of the proposed buyer, and any other information that the Company or Wefunder Admin, LLC may reasonably request. To the extent possible, such notice shall be provided through the Wefunder.com website. Any transfer of Interests shall be subject to execution by Investor and the proposed transferee of appropriate documentation, as may be required by the Company or Wefunder Admin, LLC, in their discretion. Investor further acknowledges that pursuant to the LLC Agreement, Wefunder Admin, LLC (as Series Manager of the SPV), may impose additional restrictions on or prohibit the Transfer of Interests for any reason or no reason, in its sole discretion.

9.8. Repurchase. In the event that the SPV or any Administrator determines that it is likely that within twelve (12) months the securities of the SPV or the Company will be held of record by a number of persons that would require the SPV or the Company to register a class of its equity securities under the Securities Exchange Act of 1934, as amended ("Exchange Act"), as required by Section 12(q) or 15(d) thereof, the SPV shall have the option to repurchase the Interests from each Investor to the extent necessary to avoid the requirement to register a class of its securities under the Exchange Act. Such repurchase of Interests shall be for the greater of (i) the purchase price of the Interests, or (ii) the fair market value of the Interests, as determined by an independent appraiser of securities chosen by the Administrator. Any such repurchase may only occur with the consent of Wefunder Admin, LLC, as Series Manager of the SPV.

9.9. Governing Law. Consent to Jurisdiction. Notwithstanding the place where this Subscription Agreement may be executed by any of the parties hereto, the parties expressly agree that all the terms and provisions hereof shall be construed under the laws of the State of Delaware. Any action or proceeding brought by the SPV or any SPV service provider against one or more investors in the SPV relating in any way to this Subscription Agreement or the LLC Agreement may, and any action or proceeding brought by any other party against the SPV or any SPV service provider relating in any way to this Subscription Agreement or the Company Information shall, be brought and enforced in the state courts of the State of Delaware located in Wilmington or (to the extent subject matter jurisdiction exists therefore) in the courts of the United States located in the District of Delaware; and the Investor and the SPV irrevocably submit to the jurisdiction of both such state and federal courts in respect of any such action or proceeding. The Investor and the SPV irrevocably waive, to the fullest extent permitted by law, any objection that they may now or hereafter have to laying the venue of any such action or proceeding in the courts of the State of Delaware located in Wilmington or in the courts of the United States located in the District of Delaware and any claim that any such action or proceeding brought in any such court has been brought in an inconvenient forum.

9.10. Severability. If any provision of this Subscription Agreement is invalid or unenforceable under any applicable law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such applicable law. Any provision hereof that may be held invalid or unenforceable under any applicable law shall not affect the validity or enforceability of any other provisions hereof, and to this extent the provisions hereof shall be

severable.

9.11. **Headings.** The headings in this Subscription Agreement are for convenience of reference only, and shall not limit or otherwise affect the meaning hereof.

9.12. **General.** This Subscription Agreement shall be binding upon the Investor and the legal representatives, successors and assigns of the Investor, shall survive the admission of the Investor as a member of a SPV, and shall, if the Investor consists of more than one person, be the joint and several obligation of all such persons.

[Remainder of page intentionally left blank. Signature page follows.]

The undersigned have executed this instrument as of the date first above written.

SPV

Osnovum I, as series of Wefunder SPV, LLC
By: Wefunder Admin, LLC, its Manager

By: [Signature: "Tovnaker Signature"] Date: [Signature: "0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000"]

Name: Nicholas Tommarello Title: Chief Executive Officer

Investor

[INVESTOR NAME]

By: [Signature: "Investor Signature"] Date: [Signature: "00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000"]

CONTACT INFORMATION:

Name: [INVESTOR NAME]

Mailing Address:

City:

Country:

E-mail:

TERMS APPENDIX FOR THE PURCHASE OF OsNovum SECURITIES BY Osnovum I. A SERIES OF WEFUNDER SPV, LLC, A DELAWARE LIMITED LIABILITY COMPANY

Type of Security: Priced Round

Terms $40 per share and a $19.5M pre-money valuation

{ To view a copy of the contract, please see <b>Appendix B, Investor Contracts</b> of the Form C. The latest Form C or C/A filing be found here:<br/> <a target='blank' href="https://www.sec.gov/cgi-bin/browse-edgar?company=&amp;match=&amp;filenum=020-34287&amp;State=&amp;Country=&amp;SIC=&amp;myowner=exclude&amp;action=getcompany">https://www.sec.gov/cgi-bin/browse-edgar?company=&amp;match=&amp;filenum=020-34287&amp;State=&amp;Country=&amp;SIC=&amp;myowner=exclude&amp;action=getcompany</a> }

**Attachment 5:** `document_5.pdf`

OSNOVUM

YEAR ENDED DECEMBER 31, 2024

Dennis K. Meservy
CERTIFIED PUBLIC ACCOUNTANT

601 E. CHARLESTON BLVD., STE. 101
LAS VEGAS, NV 89104-1508
CPA

# OSNOVUM

## YEAR ENDED DECEMBER 31, 2024

### See Independent Accountant’s Review Report

## CONTENTS

|  | Page |
| --- | --- |
| Independent accountant’s report | 1-2 |
| Financial statements: |  |
| Balance sheet | 3 |
| Statement of income and retained earnings | 4 |
| Statement of stockholders’ equity | 5 |
| Statement of cash flows | 6 |
| Notes to financial statements | 7-8 |

Member
American Institute of
Certified Public Accountants
601 E. Charleston Blvd., Ste. 101
Las Vegas, Nevada 89104-1508
Dennis K. Meservy
Certified Public Accountant
CPA
Member
Nevada Society of
Certified Public Accountants
(702) 385-7080
Fax (702) 385-7744

# INDEPENDENT ACCOUNTANT'S REVIEW REPORT

To Management
OsNovum
Las Vegas, Nevada

I have reviewed the accompanying financial statements of OsNovum, which comprise the balance sheet as of December 31, 2024, and the related statements of income and retained earnings, stockholder's equity and cash flows for the year then ended, and the related notes to the financial statements. A review includes primarily applying analytical procedures to management's financial data and making inquiries of company management. A review is a substantially less in scope than an audit, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, I do not express such an opinion.

## Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of the financial statements that are free from material misstatement whether due to fraud or error.

## Accountant's Responsibility

My responsibility is to conduct the review in accordance with Statements on Standards for Accounting and Review Services promulgated by the Accounting and Review Services Committee of the AICPA. Those standards require me to perform procedures to obtain limited assurance as a basis for reporting whether I am aware of any material modifications that should be made to the financial statements for them to be in accordance with the accounting principles generally accepted in the United States of America. I believe that the results of my procedures provide a reasonable basis for my conclusion.

I am required to be independent of OsNovum and to meet my other ethical responsibilities, in accordance with the relevant ethical requirements related to my review.

Accountant's Conclusion

Based on my review, I am not aware of any material modifications that should be made to the accompanying financial statements in order of them to be in accordance with accounting principles generally accepted in the United States of America.

Dennis K. Meekel
Las Vegas, Nevada

June 11, 2025

# OSNOVUM

# BALANCE SHEET

December 31, 2024

See Independent Accountant's Review Report

# ASSETS

| Current assets: |  |
| --- | --- |
| Cash in checking | $9,366 |
| Cash in savings | 74 |
| Total current assets | 9,440 |
| Total assets | $9,440 |

# LIABILITIES AND STOCKHOLDERS' EQUITY

| Current liabilities Liabilities | $0 |
| --- | --- |
| Total current liabilities | 0 |
| Shareholder loan payable | 0 |
| Total liabilities | 0 |
| Common stock, $.00001 per share, 537,000 shares authorized and 0 shares outstanding | 0 |
| Preferred stock, $.00001 per share, 37,000 shares authorized and 10,049 shares outstanding (Note 1) | 0 |
| Additional paid in capital (Note 1) | 279,035 |
| Retained earnings | (269,595) |
| Total stockholders' equity | 9,440 |
| Total liabilities and stockholders' equity | $9,440 |

The accompanying notes are an integral part of these financial statements

# OSNOVUM

## STATEMENT OF INCOME AND

## RETAINED EARNINGS

## YEAR ENDED DECEMBER 31, 2024

See Independent Accountant’s Review Report

| Revenues: | 12-31-24 |
| --- | --- |
| Revenues | $0 |
| Interest income | 0 |
| Total revenues: | 0 |
| Expenses: |  |
| Bank charges and stock sales fees | 5,350 |
| Computer and internet | (51) |
| Professional fees | 8,110 |
| Subcontractor | 42,405 |
| Total expenses | 55,814 |
| Net income (loss) | (55,814) |
| Retained earnings, January 1 | (213,781) |
| Retained earnings, December 31 | $(269,595) |

The accompanying notes are an integral part of these financial statements

# OSNOVUM

## STATEMENT OF STOCKHOLDERS' EQUITY

### YEAR ENDED DECEMBER 31, 2024

See Independent Accountant's Review Report

|  | Common Stock | Preferred Stock | Additional Paid In Capital | Retained Earnings | Total |
| --- | --- | --- | --- | --- | --- |
| Balances at January 1, 2024 | $0 | $0 | $209,275 | $(213,781) | $(4,506) |
| Additional paid in capital |  |  | 69,760 |  | 69,760 |
| Net income (loss) |  |  |  | (55,814) | (55,814) |
| Balances at December 31, 2024 | $0 | $0 | $279,035 | $(269,595) | $9,440 |

The accompanying notes are an integral part of these financial statements

# OSNOVUM

## STATEMENT OF CASH FLOWS

### YEAR ENDED DECEMBER 31, 2024

See Independent Accountant’s Review Report

| Cash flows from operating activities: Net income (loss) | $(55,814) |
| --- | --- |
| Adjustments to reconcile net income to net cash provided in operating activities: |  |
| Accounts receivable, decrease | 0 |
| Accounts payable increase | 0 |
| Net cash used by operating activities | (55,814) |
| Cash flows from investing activities: Net cash used by investing activities | 0 |
| Cash flows from financing activities: Shareholder loan payable decrease Proceed from sale of stock | (4,643) 69,760 |
| Net cash provided by financing activities | 65,117 |
| Net decrease in cash | 9,303 |
| Cash, January 1 | 137 |
| Cash, December 31 | $9,440 |

Supplementary Disclosures:
Interest paid during year:
Interest expense $0

The accompanying notes are an integral part of these financial statements

# OSNOVUM

## NOTES TO FINANCIAL STATEMENT

DECEMBER 31, 2024

See Independent Accountant’s Review Report

1. Significant accounting policies:

**Basis of accounting:**

OsNovum’s accounts are maintained on the accrual basis of accounting. Accounts receivable and accounts payable are reflected in the accompanying financial statements. The company had no accounts receivable nor accounts payable as of December 31, 2024.

**Organization:**

OsNovum was incorporated in Wyoming on June 9, 2020.

**Company’s activities and operating cycles:**

The company provides a localized regenerative solution for poorly mineralized bones.

**Use of estimates in preparation of financial statements:**

The preparation of the accompanying financial statements in conformity with generally accepted accounting principles requires management to make certain estimates and assumptions that directly affect the results of reported assets, liabilities, revenues, and expenses. Actual results may differ from these estimates.

**Cash and cash equivalents:**

The company considers all short-term securities purchased with an original maturity of three months or less to be cash equivalents.

# OSNOVUM

## NOTES TO FINANCIAL STATEMENT, CONTINUED

DECEMBER 31, 2024

See Independent Accountant’s Review Report

1. Significant accounting policies, continued:

Federal income taxes:

As of December 31, 2024, the Company had federal income taxes amounting to $0. Therefore, no provision or liability for federal income taxes has been included in the financial statements.

Significant accounting policies, continued:

Concentrations:

The Company maintains its cash balance at one financial institution. Federal Deposit Insurance Corporation (FDIC) insures accounts to a maximum $250,000. As of December 31, 2024, the company’s uninsured cash balance totals $0.

Subsequent events:

Subsequent events were evaluated through June 11, 2025, which is the date the financial statements were available to be issued.

Preferred stock/Additional paid in capital:

OsNovum has issued 7,975 shares of series seed-1 preferred stock sold at a price per share of $25 and 330 shares of series seed-2 preferred stock sold at a price per share of $30 through 2021. Also, Osnovum issued 1,744 shares of preferred stock at a price per share of $40 in 2024. Thus, 10,049 shares have been issued for $.10 (10,049 x .00001 per share) and additional paid in capital amounting to 279,034.90 (7,925 x $24.99999, 330 x $29.99999 and 1,744 x 39.99999).

**Attachment 6:** `document_6.pdf`

OSNOVUM

YEAR ENDED DECEMBER 31, 2023

Dennis K. Meservy
CERTIFIED PUBLIC ACCOUNTANT

601 E. CHARLESTON BLVD., STE. 101
LAS VEGAS, NV 89104-1508
CPA

OSNOVUM
YEAR ENDED DECEMBER 31, 2023
See Independent Accountant's Review Report

CONTENTS

|  | Page |
| --- | --- |
| Independent accountant's report | 1-2 |
| Financial statements: |  |
| Balance sheet | 3 |
| Statement of income and retained earnings | 4 |
| Statement of stockholders' equity | 5 |
| Statement of cash flows | 6 |
| Notes to financial statements | 7-8 |

Member
American Institute of
Certified Public Accountants
Dennis K. Mesery
Certified Public Accountant
CPA
Member
Nevada Society of
Certified Public Accountants
601 E. Charleston Blvd., Ste. 101
Las Vegas, Nevada 89104-1508
(702) 385-7080
Fax (702) 385-7744

# INDEPENDENT ACCOUNTANT'S REVIEW REPORT

To Management
OsNovum
Las Vegas, Nevada

I have reviewed the accompanying financial statements of OsNovum, which comprise the balance sheet as of December 31, 2023, and the related statements of income and retained earnings, stockholder's equity and cash flows for the year then ended, and the related notes to the financial statements. A review includes primarily applying analytical procedures to management's financial data and making inquiries of company management. A review is a substantially less in scope than an audit, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, I do not express such an opinion.

## Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of the financial statements that are free from material misstatement whether due to fraud or error.

## Accountant's Responsibility

My responsibility is to conduct the review in accordance with Statements on Standards for Accounting and Review Services promulgated by the Accounting and Review Services Committee of the AICPA. Those standards require me to perform procedures to obtain limited assurance as a basis for reporting whether I am aware of any material modifications that should be made to the financial statements for them to be in accordance with the accounting principles generally accepted in the United States of America. I believe that the results of my procedures provide a reasonable basis for my conclusion.

I am required to be independent of OsNovum and to meet my other ethical responsibilities, in accordance with the relevant ethical requirements related to my review.

Accountant's Conclusion

Based on my review, I am not aware of any material modifications that should be made to the accompanying financial statements in order of them to be in accordance with accounting principles generally accepted in the United States of America.

Dennis K. Masey

Las Vegas, Nevada

June 10, 2024

# OSNOVUM

# BALANCE SHEET

December 31, 2023

See Independent Accountant's Review Report

# ASSETS

| Current assets: |  |
| --- | --- |
| Cash in checking | $63 |
| Cash in savings | 74 |
| Total current assets | 137 |
| Total assets | $137 |

# LIABILITIES AND STOCKHOLDERS' EQUITY

| Current liabilities Liabilities | $0 |
| --- | --- |
| Total current liabilities | 0 |
| Shareholder loan payable | 4,643 |
| Total liabilities | 4,643 |
| Common stock, $.00001 per share, 537,000 shares authorized and 0 shares outstanding | 0 |
| Preferred stock, $.00001 per share, 37,000 shares authorized and 8,305 shares outstanding (Note 1) | 0 |
| Additional paid in capital (Note 1) | 209,275 |
| Retained earnings | (213,781) |
| Total stockholders' equity | (4,506) |
| Total liabilities and stockholders' equity | $137 |

The accompanying notes are an integral part of these financial statements

# OSNOVUM

# STATEMENT OF INCOME AND

# RETAINED EARNINGS

# YEAR ENDED DECEMBER 31, 2023

# See Independent Accountant's Review Report

| Revenues: | 12-31-23 |
| --- | --- |
| Revenues | $0 |
| Interest income | 1 |
| Total revenues: | 1 |
| Expenses: |  |
| Bank charges | 42 |
| Dues and subscriptions |  |
| Computer and internet | 2,665 |
| Laboratory supplies and materials | 337 |
| Licenses |  |
| Pharmaceuticals |  |
| Professional fees | 4,442 |
| Repairs and maintenance |  |
| Subcontractor | 15,165 |
| Travel and lodging |  |
| Total expenses | 22,651 |
| Net income (loss) | (22,650) |
| Retained earnings, January 1 | (191,131) |
| Retained earnings, December 31 | $(213,781) |

The accompanying notes are an integral part of these financial statements

# OSNOVUM

## STATEMENT OF STOCKHOLDERS' EQUITY

### YEAR ENDED DECEMBER 31, 2023

See Independent Accountant's Review Report

|  | Additional |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Common Stock | Preferred Stock | Paid In Capital | Retained Earnings | Total |  |
| Balances at January 1, 2023 | $0 | $0 | $209,275 | $(191,131) | $18,144 |  |
| Net income (loss) |  |  |  | (22,650) | (22,650) |  |
| Balances at December 31, 2023 | $0 | $0 | $209,275 | $(213,781) | $(4,506) |  |

The accompanying notes are an integral part of these financial statements

# OSNOVUM

## STATEMENT OF CASH FLOWS

### YEAR ENDED DECEMBER 31, 2023

See Independent Accountant’s Review Report

| Cash flows from operating activities: Net income (loss) | $(22,650) |
| --- | --- |
| Adjustments to reconcile net income to net cash provided in operating activities: |  |
| Accounts receivable, decrease | 0 |
| Accounts payable increase | 0 |
| Net cash used by operating activities | (22,650) |
| Cash flows from investing activities: Net cash used by investing activities | 0 |
| Cash flows from financing activities: Shareholder loan payable increase | 4,643 |
| Net cash provided by financing activities | 4,643 |
| Net decrease in cash | (18,007) |
| Cash, January 1 | 18,144 |
| Cash, December 31 | $137 |

Supplementary Disclosures:
Interest paid during year:
Interest expense $0

The accompanying notes are an integral part of these financial statements

# OSNOVUM

## NOTES TO FINANCIAL STATEMENT

DECEMBER 31, 2023

See Independent Accountant’s Review Report

1. Significant accounting policies:

Basis of accounting:

OsNovum’s accounts are maintained on the accrual basis of accounting. Accounts receivable and accounts payable are reflected in the accompanying financial statements. The company had no accounts receivable nor accounts payable as of December 31, 2023.

Organization:

OsNovum was incorporated in Wyoming on June 9, 2020.

Company’s activities and operating cycles:

The company provides a localized regenerative solution for poorly mineralized bones.

Use of estimates in preparation of financial statements:

The preparation of the accompanying financial statements in conformity with generally accepted accounting principles requires management to make certain estimates and assumptions that directly affect the results of reported assets, liabilities, revenues, and expenses. Actual results may differ from these estimates.

Cash and cash equivalents:

The company considers all short-term securities purchased with an original maturity of three months or less to be cash equivalents.

# OSNOVUM

## NOTES TO FINANCIAL STATEMENT, CONTINUED

### DECEMBER 31, 2023

See Independent Accountant’s Review Report

1. Significant accounting policies, continued:

Federal income taxes:

As of December 31, 2023, the Company had federal income taxes amounting to $0. Therefore, no provision or liability for federal income taxes has been included in the financial statements.

Significant accounting policies, continued:

Concentrations:

The Company maintains its cash balance at one financial institution. Federal Deposit Insurance Corporation (FDIC) insures accounts to a maximum $250,000. As of December 31, 2023, the company’s uninsured cash balance totals $0.

Subsequent events:

Subsequent events were evaluated through June 10, 2025, which is the date the financial statements were available to be issued.

Preferred stock/Additional paid in capital:

OsNovum has issued 7,975 shares of series seed-1 preferred stock sold at a price per share of $25 and 330 shares of series seed-2 preferred stock sold at a price per share of $30 through 2021. Thus, 8,305 shares have been issued for $.08 (8,305 x .0001 per share) and additional paid in capital amounting to 209,274.92 (7,925 x $24.99999 and 330 x $29.99999).

**Attachment 7:** `document_7.pdf`

Page 1 of 4

# Contact

www.linkedin.com/in/ danielvargasmba (LinkedIn)

# Top Skills

- Market Research
- Business Management
- Business Development

# Languages

- Spanish (Native or Bilingual)
- English (Native or Bilingual)
- German (Elementary)

# Certifications

- Nano Tips for Using ChatGPT for Business with Rachel Woods
- Google Display Ads Certification
- Nano Tips for Using ChatGPT for Marketers with Ross Simmonds
- Generative AI for Digital Marketers

# Honors-Awards

- 2nd Place Winner - Business Plan Competition
- Company Grade Officer of the Year (2015, Annual)
- Company Grade Officer of the Quarter (2015, 2nd Quarter)
- Company Grade Officer of the Quarter (2015, 4th Quarter)
- Company Grade Officer of the Quarter (2015, 2nd Quarter)

# Daniel Vargas

VP of Marketing || Non-Profit Org President || AI Enthusiast || USAF Vet || Business Nerd || Coffee Gourmand
Las Vegas, Nevada, United States

# Summary

The classic STEM nerd who wandered into the soft sciences...

Modern marketing professional equipped with an MBA, an instinct for analysis, a passion for AI, and an unbridled love of dogs!

Currently, VP of Marketing of an FDA-regulated biotech startup disrupting the field of regenerative medicine, as well as President of a "marvelous" 501(c)(3) based in Las Vegas. Former United States Air Force officer with valuable leadership skills, having managed multimillion-dollar jet fighter fleet operations.

But ask me about my coffee obsession ##

# Experience

**Ava's Avengers 501(c)(3)**

**President**
October 2018 - Present (5 years 8 months)
Las Vegas, Nevada, United States

**Ava's Avengers, 501(c)(3) - www.avasavengers.org**

We seek to bring hope and support to families with children undergoing medical treatment, while inspiring others to "find their inner hero" by getting involved in helping their own communities. Our organization is nation-wide and we strengthen our communities by donating time, raising funds, spreading awareness, and connecting families to needed resources.

- President, March 2023
- Interim President, April 2021
- Member, Board of Directors, August 2020
- Volunteer, October 2018

**SteinerBio**

**VP of Marketing**
April 2018 - Present (6 years 2 months)

Page 2 of 4

# Henderson, Nevada, United States

- Builds and executes marketing plans for B2B medical devices as a biotech startup in the field of regenerative medicine with over $300K annual revenue
- Redesigned style, layout, and features for existing startup company and its subsidiary websites, tripling average monthly traffic
- Designs/manages online marketing campaigns across platforms (Meta, Twitter, YouTube)
- Grew Facebook followers by 3x through implementation of a unified brand strategy
- Led the creative copy and visual design for the launch of a biotech subsidiary through a crowdfunding platform, successfully raising $250K in six months
- Creates A/B testing for Facebook Ad copy/design, leading to above-industry CTR rates
- Revamped semi-monthly email campaigns to increase subscriber readership and engagement by 4x
- Designed and launched several full-page print ads featured in medical journals
- Secured two new distributors to market the full product line through their network
- Utilizes SurveyMonkey to create surveys and analyze results for market research
- Designs and executes product and product demo photography and videography for online and print content
- Continuously explores and identifies new markets to target for brand reach expansion
- Develops detailed marketing literature and other sales tools distributors and events
- Adheres to the company's Quality Management System (QMS) as well as quality system regulations, standards, and procedures

# United States Air Force

Assistant Officer in Charge

2013 - 2017 (4 years)

Las Vegas, Nevada Area

Aircraft Maintenance

- Led, trained, and equipped +150 personnel to support $750 million fleet sustainment operations, projects, assignments, and strategic/operational missions

- Directed aircraft maintenance production, staff activity, and related materiel programs
- Managed maintenance and modification of aircraft to support multimillion dollar test initiatives, leading to live use in combat missions
- Managed and directed quality assurance, maintenance training, budget and resource management, analysis, facilities, shared resources, and wholesale logistics life cycle sustainment support
- Devised strategies for unit capabilities and briefed senior-level officers, leaders, and commanders on a daily basis through data/metrics analysis, personnel performance reviews, and dashboard reporting

J.B. Hunt Transport, Inc.
Pricing Administrator
2007 - 2010 (3 years)
Lowell, Arkansas

Partnership Development

- Implemented pricing strategies to sustain multimillion dollar regional/national accounts
- Supported sales force with administrative tasks: contract reviews, invoicing, collections
- Fostered strong working relationships between pricing group, sales, marketing, and ops
- Audited and resolved variances daily through queries for top level supervision reporting

University of Arkansas
Administrative Clerk
April 2005 - December 2005 (9 months)
Fayetteville, Arkansas Area

Office of Admissions

- Processed incoming undergraduate student college admissions applications and examined supporting documents for
- Fielded general public and student inquiries to assist with admissions by phone/in person
- Handled clerical tasks, filing, and operating/troubleshooting new scanners for digital recordkeeping technology launch

Columbus Consolidated Government

Page 3 of 4

Page 4 of 4

# Tax Clerk

December 2001 - April 2005 (3 years 5 months)

Columbus, Georgia, United States

Office of the Tax Commissioner

- Processed vehicle/trailer license plate and title registration for all residents of Muscogee County, Georgia
- Conducted property tax collection to generate $300K in average monthly tax revenue
- Assisted general public with tax/registration-related inquiries in person/phone/mail
- Reported directly to the Tax Commissioner with administrative tasks outside of primary duties

# Education

University of Nevada-Las Vegas

Master of Business Administration - MBA

University of Arkansas

Bachelor of Arts - BA, Sociology

University of Arkansas

Bachelor of Arts - BA, Criminal Justice

Columbus State University

Criminal Justice

**Attachment 8:** `document_8.pdf`

Gregory G. Steiner

Experience

OsNovum, CEO, Founder

June 2020 - Present

Formed the core for OsNovum by developing the research needed to apply the current technology of SteinerBio and introducing it to the treatment of osteoporotic lesions

Steiner Biotechnology, CEO

Jan 2000 - Present

Steiner Biotechnology is a company dedicated to regenerative medicine. Currently our product line is focused on regeneration of skeletal defects.

**Attachment 9:** `document_9.pdf`

# Roslynn L. Steiner

CONTACT

## EDUCATION

Norwalk High School
3.7 GPA General Education Diploma

Cerritos Jr. College
3.8 Associates of Arts Degree
2 year Register Dental Assisting Program
- Certification
- California State Registered Dental Assistant/Coronal Polishing License 36565
- X-ray License DA23
- Surgical Assisting Training in both Periodontics and Oral Surgery
- Received training and internship in: General Practice, Orthodontics, Endodontics, Pedodontics, and Prosthodontics
- Completed 272 hours of Internship at the University of Southern California Oral Surgery Department as a Surgical Assistant

Completed all the required Pre-Dental Hygiene Science Courses

## EXPERIENCE

08/15/2008-Present
**President**
Steiner Biotechnology
Henderson, NV

01/012015-Present
**Founder, OsNovum**
Formed the core for OsNovum by developing the research needed to apply the current technology of SteinerBio and introducing it to the treatment of osteoporotic lesions

2005-2008
**Supervisor, Registered Dental Assistant**
Vineyard Dental
Dr. Mickey Francis DDS
Santa Rosa, CA
Surgical Assistant Periodontics, Endodontics, and General Dentistry

2002-2005
**Supervisor, Registered Dental Assistant**
Dr. Kenneth Alford DDS
Santa Rosa, CA
Orthodontics and General Dentistry

1997-2002

Supervisor, Treatment Coordinator, Registered Dental Assistant
Dr. Robert Tradewell DDS
Rohnert Park, CA
General Dentistry

1994-1997
Supervisor, Treatment Coordinator, Registered Dental Assistant
Megdal Dental Care
Bellflower, CA
Oral Surgery and General Dentistry
Designed and organized the opening of new healthcare facilities

1990-1994
Supervisor, Registered Dental Assistant
Western Dental Belflower
Bellflower, CA
General Dentistry
Designed and organized the opening of new healthcare facilities

1990-1992
Registered Dental Assistant
Dr. Ralph Nicassio
Norwalk, CA
Orthodontics and General Dentistry

1989-1990
Registered Dental Assistant
Dr. A. Sujan DDS
Bellflower, CA
Pedodontics and General Surgery

Dental Office Supervisor Duties:
- Staff training
- Maintain an organized and clean environment at all times
- PPE’s and sterilization processes are implemented and taught to all staff members
- OSHA and safety regulations
- Record keeping and managing filing systems
- Hiring and firing of staff
- Ordering of equipment and dental materials
- Equipment and instrumentation maintenance
- Keeping daily logs for various duties
- Ensure all staff is up to date with licensing, including CE Credits
- Schedule meetings with staff, management, and doctors
- Coordinate assistants with doctors
- Coordinate and direct staff and doctors to stay on schedule
- Assist in surgery when needed
- Surgical room set up and break down

RESEARCH EXPERIENCE

Minimally invasive sinus augmentation

Steiner GG, Steiner DM, Herbias MP, Steiner R. J Oral Implantol. 2010;36(4):295-304. doi: 10.1563/AAID-JOI-D-09-00010. PMID: 20735266

The healing socket and socket regeneration.

Steiner GG, Francis W, Burrell R, Kallet MP, Steiner DM, Macias R. Compend Contin Educ Dent. 2008 Mar;29(2):114-6, 118, 120-4 passim. PMID: 18429427

**Attachment 10:** `document_10.pdf`

OsNovum

# A REGENERATIVE SOLUTION
FOR POORLY MINERALIZED BONES

www.osnovum.com

# OSTEOPOROSIS: THE SILENT EPIDEMIC

A growing epidemic threatens mobility and independence.

- 200M+ people worldwide have osteoporosis
- 8.9 million fractures annually
- 1 in 3 women over 50 will suffer a fracture

The problem isn't just big-it's growing. Patients need better solutions.

$57B spent annually on fractures in the United States alone.

![img-0.jpeg](img-0.jpeg)

# CURRENT TREATMENTS AREN'T GOOD ENOUGH

Despite billions spent, most treatments leave patients with fractures, pain, and frustration.

## Existing Treatments

- Bisphosphonates: GI issues, jawbone necrosis, atypical fractures.
- Low adherence rates: ~50% stop treatment within a year.
- Limited efficacy: Most drugs slow loss, but don't rebuild bone.

## What Patients Need

- A treatment that regenerates bone, not just preserves it.
- Safe, effective, with fewer side effects.
- High adherence and patient demand for innovation.

Osteoporosis patients deserve more than temporary solutions.
It's time for real innovation.

# THE OSNOVUM SOLUTION

Our patented molecule activates the patient's own bone growing process.

1. Our regenerative material is applied locally into an area of low bone density at risk of fracture
2. The patient's osteoblasts proliferate and absorb our compound before migrating into surrounding tissue
3. Since they are bone-growing cells, the osteoblasts increase mineral density and vitality of local and surrounding bone

![img-1.jpeg](img-1.jpeg)

![img-2.jpeg](img-2.jpeg)

Without our compound, no other material can truly stimulate bone growth.

# REGENERATIVE TECHNOLOGY

The proliferation of millions of osteoblasts is initiated upon absorbing our patented organic molecule (SL Factor) and the rapid growth of healthy, vital bone occurs.

![img-3.jpeg](img-3.jpeg)
![img-4.jpeg](img-4.jpeg)

Osteoblasts migrating into OsNovum

After six weeks, OsNovum is forming healthy vital bone

Increasing bone density enables the ability to prevent fractures.

Data
1. International Osteoporosis Foundation
2. Bone Health and Osteoporosis Foundation

# THE CONTEXT

## WORLDWIDE
Global Incidence

More than 200 million people struggle with osteoporosis across the globe.

## UNITED STATES
Nationwide Incidence

54 million Americans are at risk of an osteoporotic or osteopenic bone fracture

## U.S. HEALTHCARE
The Price of Osteoporosis

Osteoporosis is predicted to account for $25.3 billion in annual costs related to fractures

The staggering, incalculable cost of medication and loss of productivity further underscores the demand for our technology.

# PROVEN TECHNOLOGY

Our technology has already been FDA-cleared to regenerate poorly mineralized maxillofacial bone for over a decade thanks to decades of vigorous R&amp;D offered by our founders through SteinerBio.

![img-5.jpeg](img-5.jpeg)

Our performance as a seasoned market disruptor with an unrivaled innovation allows for a strong competitive edge.

It's time to take this material to the skeleton.

# CURRENT TRACTION

Upon receiving our Q submission response from the FDA on device classification and requirements, we augmented our OsNovum team with a veteran FDA principal who now works as a consultant.

We have contracted with their consulting firm and we now have a regulatory expert assisting in our De Novo application.

To have this person on our side is monumental.

![img-6.jpeg](img-6.jpeg)

U.S. Department of Health and Human

# THE MODEL

Introducing new technology into the healthcare industry will take more than just time and effort.

OsNovum will contract with leading scientists from various fields to formulate the diagnostics and treatment protocols to be utilized by the OsNovum clinics.

![img-7.jpeg](img-7.jpeg)

OsNovum Clinics exclusively focused on treatment that preserves skeletal health

# THE STATUS QUO

Because osteoporosis is poorly understood, treatment is often unsuccessful, producing undesirable and sometimes permanent side effects.

Systemic drugs are virtually the only available option for patients seeking who are at risk of or are recovering from an osteoporotic bone fracture.

Our material is target-specific, intended to be applied directly to a lesion and treated locally without the worrisome systemic effects.

Our clinics will utilize the input of clinical experts to generate the protocols needed to maintain skeletal health for a lifetime.

# GO-TO-MARKET

Upon receiving FDA clearance, our GTM strategy focuses on:

## Audience Outreach

Osteoporosis patients, healthcare providers, orthopedic specialists, pharmaceutical companies, medical device manufacturers, and research institutions

## Market Entry

Phase 1: Initial launch in major U.S. cities with high prevalence of osteoporosis

Phase 2: Expansion to key international markets in Europe and Asia

## Marketing

Digital Marketing, Public Relations, Educational Content

## Distribution Channels

Direct and Online Sales: Partnering with healthcare institutions and clinics for direct integration of our device

Distributor Partnerships: Collaborating with medical device distributors to reach a broader audience

## Strategic Partnerships

Healthcare Institutions, Pharmaceutical Companies, Research Collaborations

## Sales Team:

Dedicated Sales Force and Training Program

# OUR TEAM

![img-0.jpeg](img-0.jpeg)
ROSLYNN STEINER
PRESIDENT AND CEO

We not only have a seasoned, well-rounded team, but we have recently contracted with a former FDA assistant director and current biotech regulatory consultant to assist with our De Novo application.

![img-1.jpeg](img-1.jpeg)
DR. GREG STEINER
CHIEF SCIENCE OFFICER

![img-2.jpeg](img-2.jpeg)
DANIEL VARGAS
VP. MARKETING

OsNovum
REGENERATIVE SOLUTIONS FOR SKELETAL HEALTH

# The world needs OsNovum. Let's make it happen.

Roslynn Steiner
866.317.1348
www.osnovum.com
roslynn@steinerbio.com

Thank You

# INVESTMENT OPPORTUNITY

![img-3.jpeg](img-3.jpeg)

We are seeking $130,000 in this funding round.

The FDA is requiring a De Novo device classification request. The fee for this submission is approximately $30,000.

$20,000 in consulting fees are needed to assemble the submission that outlines how our device is of moderate risk for De Novo clearance.

If approved, we will not require any human clinical trails, but there may possibly be more laboratory testing.

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM C

### UNDER THE SECURITIES ACT OF 1933

### Issuer Information

**Is this an amendment?** Yes

**Nature of Amendment:** Adding reviewed 2024 financials and raising max target.

**Name of Issuer:** OsNovum

**Legal Status:** Corporation

**Jurisdiction of Incorporation/Organization:** WY

**Date of Organization:** 06-09-2020

**Physical Address:** 1051 Olsen St, 3611, Henderson, NV, 89011

**Issuer Website:** http://www.OsNovum.com

**Is there a Co-Issuer?:** Yes

**Intermediary Name:** Wefunder Portal LLC

**Intermediary CIK:** 0001670254

**Intermediary File Number:** 007-00033

**Intermediary CRD Number:** 283503

### Offering Information

**Compensation to Intermediary:** 7.5% of the offering amount upon a successful fundraise, and be entitled to reimbursement for out-of-pocket third party expenses it pays or incurs on behalf of the Issuer in connection with the offering.

**Financial Interest in Issuer:** No

**Type of Security Offered:** Preferred Stock

**Number of Securities Offered:** 1250

**Price per Security:** $40.00

**Method for Determining Price:** Dividing pre-money valuation $19,532,200.00 by number of shares outstanding on fully diluted basis.

**Target Offering Amount:** $50,000.00

**Oversubscription Accepted:** Yes

**Oversubscription Allocation Type:** Other

**Description of Oversubscription:** As determined by the issuer

**Maximum Offering Amount:** $200,000.00

**Deadline to Reach Target Amount:** 04-30-2026

### Annual Report Disclosure Requirements

**Current Number of Employees:** 4

**Total Assets (Most Recent Fiscal Year):** $9,440.00

**Total Assets (Prior Fiscal Year):** $137.00

**Cash & Cash Equivalents (Most Recent Fiscal Year):** $9,440.00

**Cash & Cash Equivalents (Prior Fiscal Year):** $137.00

**Accounts Receivable (Most Recent Fiscal Year):** $0.00

**Accounts Receivable (Prior Fiscal Year):** $0.00

**Short-Term Debt (Most Recent Fiscal Year):** $0.00

**Short-Term Debt (Prior Fiscal Year):** $0.00

**Long-Term Debt (Most Recent Fiscal Year):** $0.00

**Long-Term Debt (Prior Fiscal Year):** $4,643.00

**Revenues/Sales (Most Recent Fiscal Year):** $0.00

**Revenues/Sales (Prior Fiscal Year):** $0.00

**Cost of Goods Sold (Most Recent Fiscal Year):** $0.00

**Cost of Goods Sold (Prior Fiscal Year):** $0.00

**Taxes Paid (Most Recent Fiscal Year):** $0.00

**Taxes Paid (Prior Fiscal Year):** $0.00

**Net Income (Most Recent Fiscal Year):** $-55,814.00

**Net Income (Prior Fiscal Year):** $-22,650.00

**Jurisdictions Offered:**

ALABAMA, ALASKA, ARIZONA, ARKANSAS, CALIFORNIA, COLORADO, CONNECTICUT, DELAWARE, DISTRICT OF COLUMBIA, FLORIDA, GEORGIA, HAWAII, IDAHO, ILLINOIS, INDIANA, IOWA, KANSAS, KENTUCKY, LOUISIANA, MAINE, MARYLAND, MASSACHUSETTS, MICHIGAN, MINNESOTA, MISSISSIPPI, MISSOURI, MONTANA, NEBRASKA, NEVADA, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NEW YORK, NORTH CAROLINA, NORTH DAKOTA, OHIO, OKLAHOMA, OREGON, PENNSYLVANIA, RHODE ISLAND, SOUTH CAROLINA, SOUTH DAKOTA, TENNESSEE, TEXAS, UTAH, VERMONT, VIRGINIA, WASHINGTON, WEST VIRGINIA, WISCONSIN, WYOMING, B5, GU, PR, VI, 1V

### Signatures

**Issuer:** OsNovum

**Signature:** Gregory Steiner

**Title:** Chief Science Officer

---

**Signature:** Gregory Steiner

**Title:** Chief Science Officer

**Date:** 06-18-2025

---

**Signature:** Roslynn Steiner

**Title:** President

**Date:** 06-18-2025

---

**Signature:** Daniel Vargas

**Title:** VP of Marketing

**Date:** 06-18-2025